Browse Month: May 2018

Progressive Engineer: Engineering Firms – New Jersey, pharmaceutical firms.#Pharmaceutical #firms

NEW JERSEY

Pharmaceutical firms Civil

A.G. Lichtenstein Associates, Inc.

Amercom Corp. Consulting Engineers

Arora and Associates, P.C.

Bach Associates, P.C.

Pharmaceutical firmsBohler Engineering Construction Inc.

Bohren and Bohren Engineering Associates, Inc.

Camp Dresser McKee Inc.

Charles A. Manganaro Consulting Engineers, P.C.

Civil Dynamics, Inc.

Crew Engineers, Inc.

Engineering Technologies, Inc.

Fletcher Engineering, Inc.

Frank R. Holtaway Son, Inc.

Pharmaceutical firmsGannett Fleming, Inc.

Garden State Surveying, Engineering Planning, Inc.

Geod Consulting, Inc.

Goldenbaum Baill Associates, Inc.

Goodkind O’Dea, Inc.

Harold E. Pellow Associates, Inc.

Hatch Mott Macdonald

Henderson and Bodwell

Heritage Consulting Engineers

Hopewell Valley Engineering, P.C.

Pharmaceutical firmsJames P. Purcell Associates, Inc.

John S. Truhan Consulting Engineers, Inc.

K. S. Engineers, P.C.

Langan Engineering and Environmental Services, Inc.

LS Engineering Associates Corp.

Maitra Associates, P.C.

Maser Consulting, P.A.

Massand Engineering, L.S, P.C.

McCormick Taylor, Inc.

Medina Consultants, P.C.

Pharmaceutical firmsMenlo Engineering Associates, Inc.

Montgomery Watson, Inc.

Neglia Engineering Associates

Orth-Rodgers Associates, Inc.

Page Engineering Consultants, P.C.

Parsons Brinckerhoff F.G., Inc.

Parsons Transportation Group -Steinman

RBZ Enterprises, Inc.

REDCO Engineering and Construction

Remington Vernick Engineers

Robert C. Bogart and Associates

Schommer Engineering, Inc.

SESI Counsulting Engineers

Speitel and Speitel, Inc.

Stout Caldwell Engineers, LLC

Studer and McEldowney, P.A.

Taylor, Wiseman Taylor

Thomas L. Yager Associates

Underwood Engineering Company, Inc.

Urbitran Associates, Inc.

Van Cleef Engineering Associates

Vollmer Associates, L.L.P.

Wilbur Smith Associates

Xanthus Business Innovations, L. L. C.

Pharmaceutical firms Environmental

ARCADIS Geraghty Miller

Carpenter Environmental Associates, Inc.

Environmental Resolutions, Inc.

First Environment, Inc.

Hazen and Sawyer, P.C.

Lan Associates, Inc

Malcolm Pirnie, Inc.

R. Vieser Associates, Inc.

Pharmaceutical firms Environmental / Geotechnical / Materials Testing

Haley Aldrich, Inc.

MATRIX Environmental Geotechnical Engineering, Inc.

Pharmaceutical firms Geotechnical

Frank H. Lehr Associates

Pharmaceutical firms Mechanical / Electrical / Plumbing (MEP)

Brownworth Engineering Associates

Chu and Gassman Consulting Engineers, P.C.

Crane Associates, P.C.

J.A.R. Engineering, Inc.

John C. Morris Associates, Inc.

Luongo Associates, P. A.

Point Pleasant Beach

Morehouse Engineering, Inc.

WB Engineers | Consultants PLLC is a Mechanical, Electrical, Plumbing and Fire Protection design firm. Our team of experienced engineers works on a wide array of projects, from large-scale infrastructure to corporate interiors, and is committed to providing the highest quality design and service. WB№s more than 45 employees service a diverse client base within the following industries: building owners/managers, developers, corporate, cultural, education, government, healthcare, hospitality, manufacturing, media, non-profit, residential, and retail.

See our other listings in New York and Massachusetts

Pharmaceutical firms

Pharmaceutical firms Multidisciplinary

Clough, Harbour Associates, L.L.P.

Consoer Townsend Envirodyne Engineers

Edwards and Kelcey, Inc.

Envar Services, Inc.

French & Parrello Associates, P.A.

Transforming ideas into reality for over 50 years, GAI Consultants is a 650-person, employee-owned, multidisciplined engineering and environmental consulting firm serving clients worldwide in the energy, transportation, real estate, water, municipal, government, and industrial markets from offices throughout the northeastern, midwestern, and southeastern United States.

Also see our listing in IN, KY, NC, OH, FL, PA, VA, WI, and WV

Pharmaceutical firms

Hanson Engineers Inc.

Langan Engineering and Environmental Services, Inc.

Lippincott Jacobs Consulting Engineers

Pharmaceutical firmsLouis Berger Group, Inc.

Maguire Group, Inc.

Michael Baker Jr., Inc.

Paulus, Sokolowski Sartor, Inc.

Pennoni Associates, Inc.

Sharp Design, Inc.

T M Associates

TAMS Consultants, Inc.

Tighe, Doty, Carrino, P.A.

Urban Engineers, Inc.

Pharmaceutical firms Specialty

Barer Engineering, P.A.

Bernard R. Berson, PE, LS, PP

Facilities Management Engineering, Inc.

Intertech Associates, Inc.

Lewis S. Goodfriend Associates

Nielsen-Wurster Group, Inc.

Ostergaard Acoustical Associates

Richard L. Baughman Associates

SWK Pavement Engineering, Inc.

Pharmaceutical firms Structural

Aaes Engineering, Inc. provides civil/structural/architectural design services including conceptual and detail design, value engineering, inspection, and preparation of reports for existing facilities. We also provide owner s engineer services for commercial and industrial applications such as pharmaceutical, power, chemical, and cryogenic installations. We work on a wide array of projects, from large-scale industrial plants to structural inspection of commercial facilities. Our engineering design product is based on simplicity, safety, efficiency and cost effectiveness.

Pharmaceutical firms





Ricerca di professionisti – Offerte di lavoro – Technical Hunters, pharma engineering.#Pharma #engineering

pharma engineering

Pharma engineering

CONOSCENZA DI EDA TOOL (PREFERIBILMENTE ALTIUM DESIGNER)CONOSCENZA LINGUAGGI DI PROGRAMMAZIONE C/C++ PER DISPOSITIVI EMBEDDED (SENZA OS E CON OS – LINUX/ANDROID/REAL TIME) E TOOL DI. Pharma engineering

Business development dell’area di compentenza;Gestione di clienti Corporate;Mansioni di back office e gestione del cliente. Pharma engineering

AttivitГ di Business Development sul territorio di riferimento (Lombardia) per i prodotti/servizi aziendali;Gestione del cliente in fase pre e post vendita;Reportistica per la direzione;Trasferte. Pharma engineering

sviluppo software in ambito IoT dalla fase di definizione delle specifiche fino alla release;garantire la qualitГ e la funzionalitГ del software;produzione di scenari di test in collaborazione con. Pharma engineering

sviluppo software dalla fase di definizione delle specifiche fino alla release;garantire la qualitГ e la funzionalitГ del software;produzione di scenari di test in collaborazione con il dipartimento. Pharma engineering

Partecipare alle riunioni del team per definire l’ingegneria del progetto insieme al PM;Eseguire studi di fattibilitГ e dimensionamento della macchina rotante;Collaborare con clienti, appaltatori. Pharma engineering

Delineare le specifiche tecniche che definiscano i prodotti di acquisto; Trattative con i fornitori; Gestione degli acquisti;. Pharma engineering

Assicurare la funzionalitГ ed efficienza degli impianti produttivi e delle infrastrutture all’interno dello stabilimento;Gestire le dinamiche legate alle persone operative in produzione. Pharma engineering





European pharmaceutical regulatory affairs experts – Pharma-EU, s, pharma agencies.#Pharma #agencies

Pharma-EU.com: Pharmaceutical Regulatory Solutions for the European Union

Pharma agencies

Consultations with patients regarding the package information leaflets. Guaranteed acceptance across the EU for National, MRP, DCP and CPs.

Pharma agencies

Previously tested PILs can be used to support other PILs to create readability testing exemptions.

Pharma agenciesReadability Testing of Package Information Leaflets and Bridging for the Generic Industry – download (285 kB)

European Regulatory Pharmaceutical Consulting Services

Pharma agencies

We can reformat and submit your pharmaceutical’s dossier to any member state in eCTD or CTD format.

Pharma agencies

Our regulatory managers have proven their experience in coordinating and completing European procedures.

Pharma agencies

We can work on-site as well as off-site to coordinate variations and maintenance of existing licenses.

Pharma agencies

Expert support Module 1 for centralized, decentralized, mutual recognition and national procedures.

Pharma agencies

We translate medical documents to all European languages using our network of certified medical translators.

Preferred Readability Testing Providers for:

Pharma agencies

Pharma agencies

Pharma agencies

Pharma agencies

Pharma agencies

Content: (c) 2008 Pharma-EU, s.r.o.

Pharma agencies





Farmacie Online Chisinau, emcure pharma.#Emcure #pharma

emcure pharma

Emcure pharma

Emcure pharma Emcure pharma

Emcure pharma

Emcure pharma

Pe categorii

Cauta medicament

Farmacie Online Chişinău

Farmacia online vă prezintă primul site farmaceutic profesionist din Republica Moldova. n farmacie şi pe site-ul nostru puteţi găsi peste 5.000 de medicamente omologate n Republica Moldova şi toate produsele parafarmaceutice necesare zi de zi. Astfel, acces nd site-ul nostru, găsiţi toate produsele de care aveţi nevoie fără a mai alerga de la o farmacie la alta şi fără a sta la coadă. Citiţi on line informaţia despre produsele care vă interesează şi comandaţi-le on line cu livrare la domiciliu sau la altă adresa.

Momentan farmacia nu functioneaza.

Noutati

Helmizol

Emcure pharma

Vagostabyl

Emcure pharma

Emcure pharma

Subtyl

Emcure pharma

Emcure pharma

Mekomorivital F

Emcure pharma

Emcure pharma

Loroben

Emcure pharma

Emcure pharma

Flurastin

Emcure pharma

Emcure pharma





Biotech Industry, Biotech News, Biotechnology Articles, pharma test.#Pharma #test

pharma test

Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

Pharma test

Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Pharma test

Cytokinetics cans lead drug after phase 3 ALS wipeout

Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

Pharma test

Step Pharma bags cash for CTPS1 autoimmune R D drive

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

Pharma test

PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

Pharma test

Amsterdam beats out Milan to host EMA

After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

Pharma test

LivaNova to offload Cardiac Rhythm unit for $190M

LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

Pharma test

DBV climbs as peanut allergy safety data come in clean

Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

Pharma test





Milliardendeal zwischen Bayer und BASF: Was machen nun die Aktien, basf pharma.#Basf #pharma

Milliardendeal zwischen Bayer und BASF: Was machen nun die Aktien?

Die beiden DAX-Konzerne Bayer und BASF haben eine Vereinbarung zum Verkauf von großen Teilen des Bayer-Geschäfts mit Saatgut- und Unkrautvernichtungsmitteln geschlossen. Der Kaufpreis soll den Angaben zufolge bei 5,9 Milliarden Euro in bar liegen. Die zu veräußernden Geschäfte erzielten im Jahr 2016 einen Umsatz von insgesamt rund 1,3 Milliarden Euro und einen operativen Gewinn (Ebitda) von 385 Millionen Euro. „Wir gehen aktiv auf die potenziellen Bedenken der Regulierungsbehörden ein, um einen erfolgreichen Abschluss der Monsanto-Transaktion zu ermöglichen“, erklärte Werner Baumann, Vorstandsvorsitzender der Bayer AG. Die Transaktion muss von den Regulierungsbehörden genehmigt werden und wird erst wirksam, wenn die Übernahme von Monsanto durch Bayer erfolgreich abgeschlossen ist. BASF erhält mit dem Kauf der Unternehmensteile auch die Produktfamilie „Libertylink“. Diese gilt als Alternative zu „Roundup Ready“ von Monsanto, zu der auch das stark umstrittene Pestizid Glyphosat gehört. Der Abschluss des Deals wird für das erste Quartal 2018 erwartet. Bayer wird den Nettoerlös der angekündigten Veräußerung zur teilweisen Refinanzierung der geplanten Übernahme von Monsanto verwenden.

„Mit dieser Akquisition ergreifen wir die Gelegenheit, äußerst attraktive Geschäftsfelder in wichtigen Feldkulturen und Märkten zu erwerben. Wir freuen uns, diese innovativen und profitablen Geschäftsfelder weiterzuentwickeln und darauf, das erfahrene und engagierte Team der Sparten Pflanzenschutz, Saatgut und Traits bei BASF willkommen zu heißen. Diese Bereiche passen exzellent zum Portfolio der BASF-Gruppe“, so Dr. Kurt Bock, BASF-Vorstandsvorsitzender.

Während die Aktie von BASF nach Bekanntgabe des Deals 0,8 Prozent ins Minus gerutscht sind, reagiert die Aktie von Bayer mit einem Kursplus von 1,3 Prozent auf 118,25 Euro. Der nächste große Widerstand für die Bayer-Aktie ist das Jahreshoch bei 123,83 Euro. Die Aktie von BASF war zuletzt im Zuge des starken Anstiegs in den vergangenen Wochen ohnehin etwas heiß gelaufen. Hier könnte sich die Korrektur nun noch etwas fortsetzen. Anleger sollten diese Phase zum Einstieg bei BASF nutzen. Bei der Bayer-Aktie bleibt DER AKTIONÄR weiterhin skeptisch. Spannend wird es hier am 26. Oktober, wenn der Zwischenbericht zum dritten Quartal veröffentlicht wird.





CMP Pharma – inspection machines production for ampoules vials injectables products, pharma test.#Pharma #test

pharma test

Via G. Galilei, 26

T + 39 0444 971716

F + 39 0444 553262

Capitale Sociale 90.000,00 i.v.

About Us

Pharma test

Our Mission towards the future

Pharma test

CMP was imagined, projected and managed with the target of becoming a high-quality company. A strong moral system, the culture of changing and improving, the values and the responsibilities are the driving force of the modern companies which want to establish themselves in the market. All CMP employees have clear that only through distinction (in method, inside and outside relationships, products and services) the company could guarantee its own future.

Pharma test

CMP believes a fundamental principle the sharing of processes, operating systems, technological innovations and each successful factor with all the people involved in the company. Information must freely circulate in the company. CMP commits itself to make clear to all external contacts its commercial policy, the goals to be reached and the tools to be used for such aim.

Respect and fulfillment of the undertakings mean highly responsible behaviors and relations with customers to match the expectations and requirements defined in the contractual relationships. When dealing with Customers CMP uses a formal and prompt communication to make well clear the features and economic value of our products/services.

Pharma test

The environmental protection and the risks prevention are fundamental points in CMP conduct. CMP promotes the energy conservation and the correct utilization of raw materials and recyclable products.

Thanks to the international relations CMP is receptive to new ideas and to the way in which people approach the views and knowledge of others both inside (among all employees) and outside (towards Customers). This does not mean that employees should be conventional or flattened towards their superiors, on the contrary everyone should be put in the proper condition to freely and openly express his/her opinion on technical and managing issues of his/her competence.





Filling Machine, Capping Machine, Labeling Machine, Bottle – Vial Washing Machine, pharma test.#Pharma #test

pharma test

Pharma test

Product Video

Pharma test Pharma test Pharma test Pharma testPharma test

Industries we serve

Pharma test

News Events

Pharma test

In the world of pharmaceutical allied filling and packaging machinery, especially referring to machinery for industries

Recent Exibitions

Pharma test

P-MEC India-2015 Stall No 32 Hall No 6 01 to 03 December 2015, Bombay Convention and Exhibition Centre, Mumbai, India

upcoming exhibitions

Pharma test

Pharma test

Our clients

  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test

Information

Our Products

Contact info

Shree Bhagwati Machtech (India) Pvt. Ltd.

9,Bhagyoday Estate, Uttam Dairy Road,

Nr Keval Kanta , Rakhial,

Ahmedabad – 380 023, Gujarat – India.

Copyright @2016. Shree Bhagwati Machtech (India) Pvt. Ltd.

SEO & Google AdWords by Opal Infotech

  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test
  • Pharma test

Pharma test





Pharmaceutical industry news, articles, jobs, reports, advice and services, pharma marketing news.#Pharma #marketing #news

First Herceptin biosimilar cleared in Europe

Pharma marketing news

Ontruzant is approved for all the same indications as Roche s blockbuster

EMA forges closer ties with HTA umbrella group

Pharma marketing newsAgrees joint work plan with the European Network for Health Technology Assessment

Novartis’ orphan drug Tasigna wins EU expanded indication

Pharma marketing newsThe CML medication can now treat paediatric patients

Amsterdam picked to host the European Medicines Agency

Pharma marketing newsBut regulator faces a challenging relocation project to depart from London

Concordia accused of overcharging NHS for thyroid drug

Pharma marketing newsThe pharma firm said to have abused its position within the UK market

Sales news

Research news

Pharma marketing news

The state of trust

Roche s Future-proofing Healthcare event shows how the current model is a complicated one

Marketing news

Regulatory news

Pharma marketing news

Revolutionising how healthcare is delivered

The big technology shift sweeping the global connection of healthcare

Appointments

Press releases

PMHub Videos

Healthcare news

The Gallery

A visual showcase of agency work. Track down an agency from the image, track down your competitors’ work, search by product or therapy area to pull up, for example, cardiovascular campaigns. Click here for a portfolio of hundreds of campaign visuals – updated regularly – free for you to reference. Agencies – to add your work to The Gallery please contact us.

Pharma marketing news

Pharma marketing news

Pharma marketing news

Pharma marketing news

Pharma marketing news

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

Pharma marketing news

Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

She arrives from US-based Dimension Therapeutics, where she was CEO

Pharma marketing news

Is AI changing the future of healthcare?

How technology is playing a big role in healthcare

Pharma marketing news

The Truth about Doctors

Pharma marketing news

Tony de Fougerolles joins Evox Therapeutics as CEO

He succeeds Dr Per Lundin who stays at the firm as COO

Pharma marketing news

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

Pharma marketing news

What value for innovation in an era dominated by affordability?

Pharma can collaborate but must be clear about its motives

Pharma marketing news

The Future of Marketing in Life Sciences: Is your function fit for purpose

Pharma marketing news

Do you want to see a magic trick?

Key points that drive behaviour change

Pharma marketing news





Buy NMDC, hold Adani Ports; sell PVR, Ajanta Pharma, avoid Lupin: Sudarshan Sukhani, dabur pharma.#Dabur

Buy NMDC, hold Adani Ports; sell PVR, Ajanta Pharma, avoid Lupin: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, “Adani Ports and Special Economic Zone after a reasonable and small correction has gone into tight and narrow consolidation. A breakout seems to be imminent here it. So hold it and so far you are not stopped out stay with it. Carry the position if necessary.”

“Big decline in oil marketing companies lead to a consolidation and a very strong rally. So that rally continues. We had a big day yesterday and chances are that new highs will be made here. So, Hindustan Petroleum Corporation (HPCL) is a buying opportunity.”

“I am amazed how NMDC reflects iron ore prices. When iron ore prices were falling down, NMDC was going through a minor bear market and now it is rallying day after day. Look at iron ore and trade NMDC. Sometimes I do that and it is very interesting either ways. So these are three buying ideas for different reasons,” he said.

“Two short sells – PVR is in a bear market of its own and Ajanta Pharma. I can pick up a pharma company everyday and say go short and it falls down and the whole sector is still in doldrums. So two sells but focus on the buys.”

Dabur pharma

Buy Sun TV Network, NIIT Tech, India Cements; sell Marico, Bharti Infratel: Sudarshan Sukhani

Buy Cipla, Hero MotoCorp, Raymond, bullish on Ashok Leyland; sell Torrent Pharma: Sudarshan Sukhani

Buy HDFC Bank, Hexaware, Britannia, Balkrishna Industries; sell Cummins India: Sudarshan Sukhani

“Lupin is part of a group which is not giving us a sense of direction. The whole pharma sector is in a bear market. Lupin is nothing. It is just one or two days of small rallies and we start thinking that it will change. It’s not changing. See the charts and see from where it has come to that lower point. It is in a bear market and should be avoided completely,” he added.

“Bharti Airtel is a positional buy. I would avoid others. PI Industries which has gone through a deep correction is giving a sense of a new rally coming up. It is not a day trade but it is worth buying into.”

“I do not think traders should enter Future Consumer now. Wait for consolidation and that will come about. Ashok Leyland has broken out of a large congestion pattern, it hit lifetime new highs. The problem with these stocks is can you buy it as a trade – that becomes difficult. As an investing idea it is excellent.”

“I would buy Indraprastha Gas (IGL) irrespective of the price. The other one is Petronet LNG where a trading call is justified. It broke out two days ago, had a mild dip yesterday and then could go long. Tata Global Beverage has been an old stock for years. It has broken out but I do not know how much more it has. So IGL is a better option.”

“GAIL India has a lot of overhead resistance and between the three, IGL and Petronet LNG are much better opportunities. Adani Power has a wonderful chart. It is building a base and a bullish head and shoulder is breaking out. It is a positional buy but it is going to go much higher. It is worth buying into.”

tags #Adani Ports and Special Economic Zone #Adani Power #Ajanta Pharma #Ashok Leyland #Bharti Airtel #Future Consumer #GAIL India #Hindustan Petroleum Corporation #Indraprastha Gas #Lupin #NMDC #Petronet LNG #PI Industries #PVR #Stocks Views #Sudarshan Sukhani of s2analytics.com #Tata Global Beverage

most popular

Dabur pharma





Aristo Pharma, cadila pharma.#Cadila #pharma

cadila pharma

Source: Stockist Secondary Audit IMS – APR MAT’17 Dataset

Cadila pharma

Corporate Standing

Source: Stockist Secondary Audit IMS – APR MAT’17 Dataset

Cadila pharma

Brand Power

Ten brands in top 300 products of Indian Pharma Market

*Rank in total Indian Pharma Market

Source : Stockist Secondary Audit IMS – APR’17 Dataset

Cadila pharma

CJ Group, pharma foods.#Pharma #foods

Pharma foods

BRIDGE

THE CJ CUP @ NINE BRIDGES

Crossing a bridge

when your dreams become reality

everyone’s dreams come true

Pharma foods

Check out what’s new at

THE CJ CUP,

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Delightful lifestyles for all time.

A selection of our best brands.

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

CJ Social Value

Pharma foods

Shaping a Successful

Pharma foods

Pharma foods

Pharma foods

Local and Global

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods

Pharma foods





Biotech Industry, Biotech News, Biotechnology Articles, pharma dynamics.#Pharma #dynamics

pharma dynamics

Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

Pharma dynamics

Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Pharma dynamics

Cytokinetics cans lead drug after phase 3 ALS wipeout

Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

Pharma dynamics

Step Pharma bags cash for CTPS1 autoimmune R D drive

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

Pharma dynamics

PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

Pharma dynamics

Amsterdam beats out Milan to host EMA

After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

Pharma dynamics

LivaNova to offload Cardiac Rhythm unit for $190M

LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

Pharma dynamics

DBV climbs as peanut allergy safety data come in clean

Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

Pharma dynamics





Turnkey Solutions for Pharma, Biotech and Containment, dabur pharma.#Dabur #pharma

dabur pharma

Dabur pharma

Pharma Biotech

Dabur pharma

Food Beverages

This is a progressively growing segment of the cleanroom industry. The market is growing quickly along with changing eating habits. Use of cleanrooms is driven by several trends and food quality being the major one.

We are one of the leading turnkey solution providers with state-of-the-art in-house designing manufacturing facilities. We have successfully completed the implementation of solutions in a variety of settings by effectively complying with the industry norms. Our clients include Pepsico and Dabur among many.

Dabur pharma

Information technology (IT)

The IT industry is an imperative segment of the total cleanroom market. And, with our extensive experience in providing turnkey solutions to various industries, we serve this sector as well.

With our rising accomplishments, we are one of the most sought-after companies for IT and semiconductor clients’ cleanroom needs. Our team collectively works towards completing the project on time, exceeding the expectations of the clients. Nokia and BYD Electronics are some of our many clients in this industry.

Dabur pharma

Defense

We offer tailored solutions in order to meet the stringent requirements of our clients of particle control in defense sector. One of our major clients is making cleanrooms affordable to all with high end quality. Creating the best client experience motivates us. We are constantly committed to improving our services, with timely delivery and sticking to required specifications. One of our major clients is Bhabha Atomic Research Centre (BARC).





Indian pharmaceutical exports: The growth story, Business Standard, pharma market access.#Pharma #market #access

Indian pharmaceutical exports: The growth story

Pharma market access

The Indian pharmaceutical industry is the largest supplier of cost effective generic medicines to the developed world. With the widest range of medicines available for exports and with the availability of the largest number of approved pharmaceutical manufacturing facilities, India is all set to become the leader of pharmaceutical exports to the world. According to IBEF, the domestic Indian pharmaceutical industry is estimated to be $ 26 billion in 2014 growing at nearly 20 percent and is expected to reach nearly $ 50 billion in 2020. .

Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber? LOGIN NOW.

What you get

On Business Standard Digital

  • Unlimited access to all content on any device through browser or app.
  • Exclusive content, features, opinions and comment пїЅ hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.
  • 18 years of archival data.

On The Wall Street Journal Online

  • Seamless access to The Wall Street Journal Online on any device with your Business Standard Digital account.
  • Experience the best of WSJ’s reporting, video and interactive features (More business executives read the journal globally than any other publication).
  • Get WSJ’s take on people and events shaping business, finance, technology, politics and culture.
  • Get WSJ newsletters in your inbox to make life easier on your busiest days.
    In this case the subscription will be valid for Business Standard Digital only without any change in the subscription price. If you have been a past Free/Registered User of The Wall Street Journal Online – You will not be eligible for the seamless account creation facility. Kindly email us your non-confidential password on The Wall Street Journal Online to enable us create your access. Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds. To cancel, communicate from your registered email id and send the mail with the request to [email protected] Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.
  • Saving calculated at the current WSJ price – US $ 1 for the first 3 months and US $ 28.99 thereafter Conversion scale 1 US$ = INR 67
  • Your access to The Wall Street Journal Online is subject to you not being an existing user of The Wall Street Journal Online.

Existing users include Current or Past Premium Users of The Wall Street Journal Online.

In this case the subscription will be valid for Business Standard Digital only without any change in the subscription price.

  • If you have been a past Free/Registered User of The Wall Street Journal Online – You will not be eligible for the seamless account creation facility. Kindly email us your non-confidential password on The Wall Street Journal Online to enable us create your access.
  • Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
  • To cancel, communicate from your registered email id and send the mail with the request to [email protected] Include your contact number for easy reference.

    Requests mailed to any other ID will not be acknowledged or actioned upon.





  • Intelligent Pharma, pharma dynamics.#Pharma #dynamics

    pharma dynamics

    Pharma dynamics

    Intelligent Pharma offers a broad range of computationally aided drug discovery services to assist you along the drug design and development pipeline .

    Pharma dynamics

    Pharma dynamics

    Over the last 10 years, Intelligent Pharma has acquired extensive experience in scientific software and solutions development specific to the needs that arise .

    Pharma dynamics

    Pharma dynamics

    Intelligent Pharma has engaged in partnerships with other expert companies with complimentary expertise in sectors including health science, chemical synthesis, .

    Events

    November 6th-8th, 2017

    November 28th-29th 2017

    Highlighted News

    October 19, 2017

    Intelligent Pharma and the Hungarian company, ChemAxon, have agreed this last October the commercialization of ChemAxon products in the Spanish territory. From now on, Intelligent Pharma will distribute the software developed by ChemAxon, the .

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Membership

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Certifications

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Parc Cientific de Barcelona

    C\Baldiri Reixac 4

    Tel: +34 934 034 551

    Our Services in Drug Design

    Technologies

    Follow Us

    Pharma dynamics Pharma dynamics Pharma dynamics

    Distributor of

    Pharma dynamics





    Fachbereich Chemie, pharmazie.#Pharmazie

    Aktuelles – Fachbereich Chemie und Pharmazie

    Um seine herausragenden akademischen Beiträge im Bereich der elektrochemischen Energiespeicherung und Energiewandlung zu würdigen, hat die National Taiwan Tech University of Science and Technology (NTUST), Taiwan Tech, Martin Winter zum Ehrenprofessor ernannt. Die feierliche Verleihung wurde durch den Präsidenten der NTUST Prof. Ching-Jong Liao im Beisein von Martin Eberts, Generaldirektor des Deutschen Instituts in Taipei, der deutschen Auslandsvertretung in Taiwan, vorgenommen.

    Pharmazie

    Pharmazie

    Anlässlich des an der WWU Münster vom 28.09 bis 30.09.2017 stattfindenden Jahreskongresses der Deutschen Gesellschaft für Phytotherapie wurde Frau Dr. Verena Spiegler (Institut für Pharmazeutische Biologie und Phytochemie) durch die Präsidentin der Gesellschaft, Frau Prof. Dr. K. Kraft, mit dem Nachwuchsförderpreis für ihre wissenschaftliche Arbeit „Anthelmintic activity of procyanidins from West African plants: From traditional medicine to phytochemistry and molecular investigations“ ausgezeichnet. Der Preis ist mit 2.000 € dotiert.

    WWU-Professor Dr. Frank Glorius erhält Arthur C. Cope Scholar Award

    Pharmazie

    Pharmazie

    Große Ehre für Frank Glorius: Die American Chemical Society (ACS) zeichnet den Professor für Organische Chemie der Westfälischen Wilhelms-Universität Münster (WWU) mit einem Arthur C. Cope Scholar Award aus. Der Preis wird für hervorragende Leistungen in der Organischen Chemie vergeben und ist mit insgesamt 45.000 US-Dollar dotiert.

    Chemiker der Universität Münster entwickeln neues Verfahren zur Synthese von fluorierten Molekülringen

    Pharmazie

    Pharmazie

    Prof. Dr. Frank Glorius und Koautoren haben eine neue, einfache Methode zur Herstellung von bislang schwer herstellbaren Fluor-tragenden dreidimensionalen molekularen Ringstrukturen entwickelt. Da diese Verbindungen zum Beispiel eine groГџe Rolle bei der Entwicklung neuer Wirkstoffe haben, ist diese in “Science” verГ¶ffentlichte neue Methode von groГџer Bedeutung.

    Biochemiker beobachten Enzyme bei der Arbeit

    Pharmazie

    Pharmazie

    Forscher um den WWU-Biochemiker Prof. Dr. Henning Mootz haben neue Erkenntnisse Гјber das Zusammenspiel der verschiedenen Komponenten von Enzym-Apparaten vorgestellt, die in lebenden Zellen zur Produktion von Proteinen dienen. Die Studie ist in “Nature Chemical Biology” verГ¶ffentlicht.

    Nachwuchsforscher treffen Chemie-Nobelpreisträger

    Seit 67 Jahren bringt die Lindauer Nobelpreisträgertagung erfolgreiche Wissenschaftler und Nachwuchsforscher zusammen. In einem mehrstufigen internationalen Auswahlverfahren haben auch drei junge Chemiker der Universität Münster überzeugt: Dr. Emily Mackay, Felix Klauck und Matthias Elinkmann hatten interessante Begegnungen und Gespräche mit den Nobelpreisträgern und anderen Wissenschaftlern ihrer Generation.

    Chemie-Olympioniken zu Gast am Fachbereich

    Pharmazie

    Pharmazie

    10 SchГјlerinnen und -schГјler aus Gymnasien in Nordrhein-Westfalen, die besonders gut bei der 2. nationalen Runde der Internationalen Chemie-Olympiade 2017 abgeschnitten haben, erhielten einen Einblick in die Forschung der Pharmazeutische Biologie und Phytochemie. Die “Olympioniken” durften die einige Alkaloide aus pulverisiertem Opium herauslГ¶sen und bestimmten die Zusammensetzung des Alkaloid-Gemisches. Dabei durften Sie viele Verfahren kennen lernen, die nicht Bestandteile des Schullehrplans sind.

    Nachwuchspreis fГјr Dr. Fabian Dielmann

    Pharmazie

    Pharmazie

    Dr. Fabian Dielmann erhielt fГјr seine herausragenden Arbeiten zu Phosphanen am 20. Juni den diesjГ¤hrigen “Preis zur FГ¶rderung des wissenschaftlichen Nachwuchses” der UniversitГ¤tsgesellschaft der WestfГ¤lischen Wilhelms-UniversitГ¤t MГјnster. Durch die Entwicklung eines neuen, besonders elektronenreichen Typs von Phosphanen mit bemerkenswerten Eigenschaften leistete er einen elementaren Beitrag auf dem Gebiet der Synthesechemie. Der Preis, der von der Sparkasse MГјnsterland Ost an insgesamt drei PreistrГ¤ger gestiftet wurde, ist mit jeweils 5000 Euro dotiert.





    M – dicament Delursan 500 mg – Guide des m – dicaments, veyron pharma.#Veyron #pharma

    Médicament Delursan 500 mg

    Page mise à jour le 25/02/2014

    Delursan 500 mg : informations générales

    DELURSAN est utilisé pour :

    • dissoudre les calculs biliaires formés de cholestérol,
    • et dans le traitement de certaines maladies chroniques du foie.

    Présentation(s) disponible(s) pour Delursan 500 mg

    plaquette(s) thermoformée(s) PVC-Aluminium de 60 comprimé(s)

    Delursan 500 mg : posologie

    Posologie

    La dose journalière dépend de votre poids et de la raison pour laquelle votre médecin a décidé de vous prescrire ce médicament.

    Si vous êtes traité pour des calculs au niveau de la vésicule biliaire, la dose est en moyenne de 1 à 2 comprimés par jour.

    Si vous êtes traité pour une maladie chronique du foie, la dose est en moyenne de 3 comprimés par jour.

    Dans tous les cas, conformez-vous strictement à l’ordonnance de votre médecin.

    Mode d’administration

    Ce médicament est utilisé par voie orale. Avalez les comprimés avec un verre d’eau sans les croquer.

    Fréquence d’administration

    Vous devez prendre vos comprimés matin et soir au cours des repas.

    Durée du traitement

    Votre médecin vous dira pendant combien de temps vous devez prendre ce traitement. Suivez scrupuleusement ses recommandations.

    Contre-indications pour Delursan 500 mg

    Ne prenez jamais DELURSAN 500 mg, comprimé pelliculé sécable dans les cas suivants :

    • Si vous êtes allergique (hypersensible) à la substance active (acide ursodésoxycholique) ou à l’un des autres composants contenus dans ce médicament..
    • Si vous ressentez des douleurs au ventre ou une colique

    Précautions d’emploi de Delursan 500 mg

    Votre médecin vous informera qu’il est impératif de ne pas dépasser la posologie maximale recommandée de 20 mg/kg/jour dans le traitement de la cholangite sclérosante primitive, en raison d’un risque de survenue d’effets indésirables graves.

    Votre médecin vous prescrira DELURSAN 500 mg après avoir effectué les examens appropriés à votre cas.

    Pour une bonne utilisation de ce médicament, il est indispensable de vous soumettre à une surveillance médicale régulière.

    Ce médicament contient un sucre (le glucose). Son utilisation est déconseillée chez les patients présentant une intolérance au glucose (maladie héréditaire rare).

    Effets secondaires connus de Delursan 500 mg

    Comme tous les médicaments, DELURSAN 500 mg est susceptible d’occasionner des effets indésirables, bien que tout le monde n’y soit pas sujet.

    Les effets suivants peuvent survenir fréquemment :

    Une diarrhée, des selles pâteuses.

    Les effets suivants peuvent survenir très rarement :

    Des douleurs abdominales.

    Des calculs biliaires calcifiés.

    Si vous remarquez des effets indésirables non mentionnés dans cette notice, ou si certains effets indésirables deviennent graves, veuillez en informer votre médecin ou votre pharmacien.

    Tenir hors de la portée et de la vue des enfants.

    Interactions de Delursan 500 mg avec d’autres médicaments

    La colestyramine (médicament utilisé pour traiter des démangeaisons associées à certaines jaunisses ou pour diminuer le taux de cholestérol dans le sang) peut diminuer l’effet de DELURSAN. Si votre médecin vous en prescrit, il convient de séparer les prises des deux médicaments de 4 heures.

    La ciclosporine (médicament utilisé pour prévenir ou traiter les rejets de greffe d’organes, de tissus, de moelle osseuse ou pour traiter certaines maladies graves des reins, de la peau ou des articulations) peut voir sa concentration modifiée dans le sang lorsqu’elle est utilisée avec DELURSAN. Votre médecin en tiendra compte et vous prescrira les analyses de sang appropriées pour surveiller cette concentration.

    Si vous prenez ou avez pris récemment un autre médicament, y compris un médicament obtenu sans ordonnance, parlez-en à votre médecin ou à votre pharmacien.

    Utilisation de Delursan 500 mg pendant la grossesse et l’allaitement

    Si vous découvrez que vous êtes enceinte pendant le traitement, consultez votre médecin car lui seul peut juger de la nécessité de le poursuivre.

    Si vous êtes enceinte ou si vous allaitez, demandez conseil à votre médecin ou à votre pharmacien avant de prendre tout médicament.

    Delursan 500 mg : composition

    Substance active

    Acide ursodésoxycholique : 500 mg

    Pour un comprimé pelliculé sécable.

    Autres composants

    Amidon de maïs, laurilsulfate de sodium, povidone, silice colloïdale anhydre, stéarate de magnésium.

    Pelliculage : dioxyde de titane (E171), glucose anhydre, hypromellose, propylèneglycol.

    Composants à effet notoire de Delursan 500 mg

    Ce médicament contient un sucre (le glucose)..

    Que faire en cas d’oubli de Delursan 500 mg ?

    Ne prenez pas de dose double pour compenser la dose que vous avez oublié de prendre.

    Que faire en cas de surdosage de Delursan 500 mg ?

    En cas de surdosage une diarrhée peut survenir. Dans ce cas, veuillez en informer votre médecin qui prendra les mesures nécessaires pour la conduite de votre traitement.

    Date de péremption de Delursan 500 mg

    Ne pas utiliser DELURSAN 500 mg après la date de péremption mentionnée sur la boîte. La date d’expiration fait référence au dernier jour du mois.

    Laboratoire(s) titulaire(s], fabricant(s) ou exploitant(s) de Delursan 500 mg

    Titulaire

    APTALIS PHARMA SAS

    Route de Bu la Prevote

    Exploitant

    APTALIS PHARMA SAS

    ROUTE DE BU – LA PREVOTE

    Fabricant

    40 BOULEVARD DE CHAMPARET

    38300 BOUGOIN JALLIEU

    Les autres médicaments hépato-biliaires

    Voir aussi : tous les médicaments Delursan

    Avertissement :

    Ce service a été réalisé à partir des informations fournies par l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) et de la Caisse nationale d’Assurance maladie (Cnam).

    Les informations et messages disponibles sur l’encyclopédie des médicaments n’ont pas vocation à être exhaustifs. Ils ne peuvent en aucun cas remplacer l’avis et la consultation d’un médecin. La responsabilité du Journal des Femmes et de CCM Benchmark Group au titre des dommages directs ou indirects ne pourra être recherchée à quelque titre que ce soit.





    Microsoft Dynamics Partner in UAE, India, US, UK – Robosoft Solutions, pharma dynamics.#Pharma #dynamics

    Discover wide range of multi-dimentional Microsoft dynamics solutions.

    Robosoft Solutions is most preferred and trusted Gold Certified Microsoft Dynamics Partner in UAE, India, UK, US providing full range of Microsoft Dynamics ERP, CRM, BI solutions.

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    PARTIAL LIST OF OUR 325+ CLIENTS

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Microsoft dynamics business solutions tailored to meet your industry specific needs.

    Our expertise and solutions help industry verticals get more efficient, maximize value and improve return on investment.

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Pharma dynamics

    Gold Certified Microsoft Dynamics Partner

    With over 17+ years of expertise, we have helped 325+ clients globally to improve organizational performance by combining our innovative use of technology and extensive business experience in various verticals to deliver solutions that has helped our clients achieve rapid and sustainable business advantage. Get to know us more!





    5 trends to watch out for in the pharma sector in 2017, buy-pharma.com.#Buy-pharma.com

    5 trends to watch out for in the pharma sector in 2017

    Buy-pharma.com

    It was a tough year for the pharma sector, which normally has a reputation for delivering credible returns even in tough market conditions. Pharma companies finished among the worst performers of 2016, alongside sectors like IT, power, real estate and capital goods.

    From the look of it 2017 is unlikely to be any easier. Pricing pressures in US the world s largest market for generic drugs tighter regulatory scrutiny by the US FDA and thereby higher compliance costs, global macro-economic uncertainty and price controls back home are expected to continue in the 2017.

    Seen another way, 2017 could perhaps provide opportunities for investors who have been looking to buy pharma shares, but found valuations prohibitive.

    Here are five things to watch out for 2017:

    Profit margins of Indian companies selling generics in the US will remain under pressure in 2017 with channel consolidation and USFDA fast tracking approvals through Generic Drug User Fee Act (GDUFA). Despite that US still remains a lucrative market with margins upwards of 20 percent. In fact in FY16 Indian companies have clocked EBITDA margins of 27 percent the highest over previous four years.

    Generic price deflation was significantly worse than expected in 2016, ranging anywhere from down 5-25 percent and resulted in several manufacturers lowering guidance. Further, the generic environment remains challenging with increased competitive pressures from new entrants and buying consortiums, and recent results suggest these challenges will continue well into 2017, which we model as another year of high single digit to low double digit price erosion, said analysts at JP Morgan in their latest report titled US Pharma 2017 Outlook .

    Analysts expect companies with new approvals, differentiated and specialty product portfolio are the ones better positioned to thrive in 2017 which means that companies will incur higher expenses on R D as was the case in 2016.

    Indian drug makers were kept busy throughout 2016 with adverse observations, warning letters and a few import alerts in extreme cases from US drug regulator. There are no two thoughts about the rising expectation of compliance to current good manufacturing practices (cGMP) by USFDA. Companies have learnt the hard way the downsides of non-compliance that include loss of market value, fresh approvals getting stuck and the cost of remediation.

    Analysts say things are getting better.

    “We believe 2016 has been a better year where the number of warning letters and import alerts for Indian sites declined compared to 2015, said a Normura report.

    For instance, the number of sites receiving import alerts is down to three vs. 12 in 2015. Similarly, the number of Indian sites receiving warning letters is eight (15 percent of all warning letters) in 2016 vs. 12 (32 percent of all warning letters in 2015),” the report said.

    Domestic pharmaceutical market – despite heavy competition was a safe bet to drug makers given the fact that market grew at 24 percent to USD 26.1 billion in 2016 and is insulated to some extent from external shocks such as currency volatility and other macro uncertainties. In 2017 analyst expect the government continue its price control policies and aim to improve quality and streamline the approval process will continue.

    One of the reasons Indian generic peers trade at premium valuations is the strong branded business in India. While we continue to remain positive on the medium term outlook for the industry, near term we expect growth to be slower, said Jefferies in their sectorial research note in August.

    This is led by increased regulations and pricing caps from the government. We expect industry growth to be in high single digits vs expectations of low-teens over the near term. Further, margins could also likely see further impact if the government s zeal of pricing key drugs expands, the report added.

    The year 2016 was a busy years for mergers and acquisitions, 2017 is expected to be no different as Indian companies try to expand into new markets, deepen their presence in existing ones, get access to manufacturing assets and fill their portfolio and technology gaps.

    “With organic-growth rates moderating and profitability plateauing, Indian companies are exploring M A that could serve as a springboard for growth,” said Moody s in their latest report.

    Other markets and Biosimilars:

    With economic slowdown, aging population and governments encouraging generic substitution Indian generic companies continue to expand in 2017 in geographies like Europe and Japan.

    The other good news in 2017 could be that with crude oil prices looking up, the problems of exchange rate volatility and steep depreciation of currencies in key export markets like such as Russia may ease.





    Home, GSK, helix pharma.#Helix #pharma

    About us

    We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

    About us

    What we do

    Our purpose and strategy

    Governance

    Comic Relief partnership

    Save the Children partnership

    We research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

    Products

    We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare

    Products

    Our consumer healthcare business has a portfolio of some of the world’s most trusted and best selling products in Pain Relief, Oral health, Respiratory, Nutrition and Skin health

    Careers

    We are a global company delivering billions of healthcare products a year. Choose your path.

    Careers

    Apprentices, students and graduates

    Postgraduate opportunities

    We are a global company delivering billions of healthcare products a year. Choose your path.

    Investors

    Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting

    Investors

    Shareholder information

    Corporate reporting

    Share price analysis

    Stock exchange announcements

    Discover our latest financial performance announcement and search for historical quarterly results materials

    Media

    Explore the latest news, different ways to stay in touch and available useful resources

    Media

    Resource centre

    Social media

    Keep up to date with our news and recent announcements

    Research

    Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines

    Research

    What we are working on

    How we discover our new products

    R D locations

    Open innovation

    Trials in people

    Sharing our research

    Research funding

    Our use of animals

    Learn more about our R D legacy involving the development of a broad range of innovative medicines, vaccines and consumer healthcare products

    Responsibility

    Responsible business is how we do business. Our special purpose is to help people do more, feel better, live longer

    Responsibility

    Health for all

    Our behaviour

    Our people

    Our planet

    Responsibility reports data

    Our part in tackling global health challenges and our aim to extend the benefits of our products to more people

    Helix pharma

    Behind the science We won’t stop until we beat HIV

    Helix pharma

    30 years and counting: the fight against HIV

    Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill – a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

    Helix pharma

    Elaine’s story: following the journey of a respiratory medicine

    Helix pharma

    3D remodelled DNA helix structure

    About us We want to help people do more, feel better, live longer.

    Today there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this.

    Press releases

    London

    Share price at

    LSE price updated every 15 minutes. Timezone BST

    Share price at

    NYSE price updated every 20 minutes. Timezone EST

    Tweets from GSK

    1. Helix pharma

    GSK GSK

    #DYK your immune system ages just like you do? Give it a helping hand, talk to your doctor about adult vaccinations… twitter.com/i/web/status/9…

    about 16 hours ago

  • Helix pharma

    GSK GSK

    Meet Elaine – she’s a champion of medicines for patients across the globe. Read her story: gsk.to/2iHSrOS… twitter.com/i/web/status/9…

    about 18 hours ago

  • Helix pharma

    GSK GSK

    Vaccination isn’t something you outgrow #VaccinateForLife Helix pharma

    Find out more

    Helix pharma

    Our products

    We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare

    Helix pharma

    Career opportunities at GSK

    Discover the work we do and the opportunities that exist, from research and development through to making our products available to those who need them

    Helix pharma

    Health for all

    Our medicines, vaccines and consumer healthcare products are improving quality of life for patients and consumers around the world.

    © 2001-2017 GlaxoSmithKline plc. All rights reserved.

    GlaxoSmithKline plc. Registered in England and Wales No. 3888792.

    Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.





  • Top 10 Companies Killing the Natural World with Pesticides, Natural Society, top ten pharma companies.#Top

    top ten pharma companies

    Top ten pharma companies

    Top ten pharma companies

    Top 10 Companies Killing the Natural World with Pesticides Also the Biggest Seed Producers

    Top ten pharma companies

    Posted on May 21, 2014

    Top ten pharma companiesIn a report released by etcgroup.org , the world’s six largest agrochemical manufacturers are also controlling the seed industry. According to the report, agrochemical is running the show, not by providing food to the people of the world, but by poisoning the seeds they provide with chemicals. All of these companies are also gene manipulating, GMO-giants. There is an inextricable link that cannot be ignored.

    • The biggest agrochemical company in the world, Bayer, is also the seventh biggest seed company.
    • The second largest agrochemical company, Syngenta, is the world’s third largest seed company.
    • The world’s biggest seed company, Monsanto, is the world’s fifth largest agrochemical company.
    • The world’s second biggest seed company – DuPont, is the world’s sixth largest agrochemical company.

    Furthermore, weed killers, like Monsanto’s RoundUp herbicide, account for one-third of the global pesticide market. About 80% of GMO seeds suck down this toxin like a crack-addict. There is no herbicide resistance in GMO plants, as we are told. There is only glyphosate and herbicide addiction . This is why Dow is making a new herbicide called Enlist Duo. It is because the pests are now becoming immune to glyphosate, and even greater toxins will have to be used to destroy the super-bugs created by these poisons.

    If you’ve ever worked with heavy drug-addicted individuals, they will deny there is a problem, and seek greater and greater doses of their ‘drug’ in order to get the same high. The agroscience industry has created the same paradigm. The worldwide market for agrochemicals grows another 10% every year. It’s a 40 billion dollar/year market – to sell the world these chemicals.

    Despite sky-rocketing fuel and fertilizer costs, high grain prices created soaring demand for commercial seeds and pesticides in 2007. Today’s GMO seed sales are chump change in comparison to herbicides and pesticides, but they keep a farmer addicted to the chemicals these idiots sell. Pesticide sales are up all over the world, particularly in South America.

    Furthermore, two GMO crops meant for biofuel (ethanol derived from GMO corn being the largest) boosted sales for the world s largest pesticide companies the last few years – in large part due to the subsidy-driven boom supported by an infiltrated government.

    Report from ETC Group (extracts only)





    Sualin (50 Tablets) by Hamdard at Madanapalas, surya pharma.#Surya #pharma

    surya pharma

    Surya pharma

    Surya pharmaANIMAL CARE

    Surya pharmaATTARS

    Surya pharmaAYURVEDIC BEAUTY

    Surya pharmaAYURVEDIC JAMS

    Surya pharmaAYURVEDIC SOAP

    Surya pharmaAYURVEDIC TEAS

    Surya pharmaBABY CARE

    Surya pharmaBODY PRODUCTS

    Surya pharmaCHILD CARE

    Surya pharmaDENTAL CARE

    Surya pharmaDISEASE

    Surya pharmaEQUIPMENT

    Surya pharmaEYE DROPS

    Surya pharmaGIFT VOUCHERS

    Surya pharmaHAIR OILS

    Surya pharma HERBAL MEDICINES

    Surya pharmaAPHRODISIAC

    Surya pharmaHERBAL SHAMPOO

    Surya pharmaHERBAL SMOKING

    Surya pharmaHOMEOPATHY

    Surya pharmaINCENSE

    Surya pharmaMASSAGE OILS

    Surya pharmaMEDICATED GHEE

    Surya pharmaMETABOLISM

    Surya pharmaMOTHER CARE

    Surya pharmaNASYA OIL

    Surya pharmaORGANIC FOODS

    Surya pharmaOTHER OILS

    Surya pharmaRASAYANAS

    Surya pharmaSINGLE HERBS

    Surya pharmaSKIN CARE

    Surya pharmaSOWA RIGPA

    Surya pharmaTIBETAN MEDICINE

    Surya pharmaVAJIKARANA

    Surya pharma





    CBC News – Canada s pharma companies disclose payments to doctors for 1st time, top

    Top ten pharma companies

    Critics say voluntary move falls short of any real transparency

    Posted:Jun 20, 2017 9:38 PM ET

    Top ten pharma companies

    Canadians were given a glimpse at the millions of dollars doctors receive each year from pharmaceutical companies, when 10 of the country’s largest firms voluntarily disclosed the figures online. But critics are decrying the lack of details around those numbers. Joe Raedle/Getty Images

    Related

    Related Stories

    For the first time, Canadians have been given a glimpse at the millions of dollars doctors receive from pharmaceutical companies each year — though critics say the move stops far short of true transparency.

    Ten of Canada’s largest drug companies voluntarily released information about how much money they give physicians, posting the disclosures to their websites Tuesday. The participating companies were:

    • AbbVie Corp.
    • Amgen Canada Inc.
    • Bristol-Myers Squibb Canada
    • Eli Lilly Canada Inc.
    • Gilead Sciences Canada, Inc.
    • GSK Canada (GlaxoSmithKline)
    • Hoffmann-La Roche Ltd. (Roche Canada)
    • Merck Canada Inc.
    • Novartis Pharmaceuticals Canada Inc.
    • Purdue Pharma Canada

    But the companies did not disclose specific names, nor did they list the reasons for the payments. Some companies disclosed data for three months, others chose six months, and four disclosed payments for one year.

    It was a disappointment for those who have been calling for greater transparency in the pharmaceutical industry.

    “This information is useless,” said Matthew Herder, director of the Health Law Institute at Dalhousie University. “To me, it seems like it’s a PR strategy, not actually any effort to improve transparency.”

    Top ten pharma companies

    Matthew Herder, director of the Health Law Institute at Dalhousie University, called Tuesday’s disclosure figures ‘useless.’ (Rachael Kelly/Dalhousie University)

    ‘Canada is lagging behind’

    Innovative Medicines Canada, the trade group that represents more than 50 pharma companies, had endorsed the disclosure initiative. But ultimately only 10 companies decided to follow its recommendation.

    And only four released the full amount they paid doctors in 2016.

    ​The voluntary disclosure comes amidst growing international pressure for transparency in pharma-physician financial relationships.

    In the U.S., any transfer of value to a doctor exceeding $10 must be disclosed by law. The information is publicly available on a searchable website, with details about travel, meals and other reasons for the payments. There are similar laws in France, Portugal, Denmark and other European countries.

    “Unfortunately Canada is lagging behind,” said Dr. Andrew Boozary, a Toronto physician who leads the Open Pharma campaign, which calls on Ottawa to require mandatory disclosure in Canada.

    “The backbone of any physician-patient relationship is trust. Where there could be perceived conflicts, where this is not public, where this is confidential or clandestine for whatever reason, [it] can really start to erode that.”

    Top ten pharma companies

    Dr. Andrew Boozary is the Toronto-based physician behind the Open Pharma campaign, calling on Ottawa to require mandatory disclosure in Canada. (University of Toronto)

    Boozary says Tuesday’s disclosure fails to answer important questions about why the doctors are being paid.

    “There are reasons why there is engagement between prescribers and drug companies, but we don’t know the extent. We don’t know the range. We don’t know what it’s for,” he said. “And today’s … announcement doesn’t move us any closer to that.”

    Calls for mandatory disclosure

    GSK Canada, which kickstarted the program, agrees the disclosure doesn’t go far enough. In a statement to CBC News, the company’s president called for greater transparency.

    “Speaking on behalf of GSK, we need individual disclosure that is mandatory, transparent and applied broadly across the entire industry,” said Paul Lirette.

    Despite that call for wider disclosure, GSK did not provide any additional details about its own payments.

    “We have pretty solid evidence over a long period of time, in several different places that suggest these kinds of relationships do have an impact,” Herder said.

    “The issue has to do with the independence of the medical profession. That’s why we can’t rely on industry to lead this kind of policy initiative. We have to have it from government.”

    Top ten pharma companies

    A look at some of the reasons doctors may receive money from pharmaceutical companies. (CBC News)

    In Ottawa, Health Minister Jane Philpott said while it would be helpful for Canadians to know if there is a financial relationship between doctors and drug companies, the issue is a provincial one.

    “Obviously, as a family doctor, I understand the importance of Canadians being aware of the relationship that doctors have with pharmaceutical companies,” she said. “But as it relates to the regulation of health professionals, this would be something I would leave to the jurisdiction of my provincial counterparts.”

    In a statement, Innovative Medicines Canada president Pamela Fralick said the pharmaceutical industry lobby group would be open to a wider discussion about disclosures.

    “Given improved access and affordability of medicines is the end goal we all share, then we do need a much more comprehensive conversation — a conversation that industry is ready and willing to have with our government stakeholders and partners within the health-care sector.”

    The four companies that reported full-year payments to health-care professionals in 2016 were:

    The five companies that disclosed what they paid doctors over a six-month period (July to December 2016) were:

    And Eli Lilly disclosed doctor-link payments for the last three months of 2016 (October to December), totalling $1,197,926.





    India Pharma 2018, 3rd International Exhibition And Conference On Pharmaceutical Industry, Conference, Event, B2B, Bengaluru

    pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    • Host State Pharma international
    • Event Patron Pharma international
    • Principal Sponsor Pharma international
    • Principal Sponsor Pharma international
    • Co-Sponsor Pharma international
    • Associate Sponsor Pharma international
    • Regitration Counter Sponsor Pharma international
    • Gate Sponsor Pharma international
    • Strategic Partner Pharma international
    • Strategic Partner Pharma international
    • Supporting Association Pharma international

    Major event to increase overall growth of Pharma sector including exports and focus on increase of Domestic production in the sector by Government of India & FICCI, with the active participation from all Stakeholders.

    Provide a platform to global investment community to connect with stakeholders in Pharma sector in India, Central and State Governments, leading business leaders and top executives from the industry, academics and experts from the world.

    Encourage ‘Make in India’- for manufacturing of Drugs and Pharmaceutical Machines.

    INDIA PHARMA 2018 covers the whole process of Pharmaceutical Manufacturing, from various kind of manufacturing/processing machineries to Lab Equipment, Analytical Instruments, APIs and other total solutions.

    Pharma international

    Post Show Report

    Pharma international

    Floor Plan

    Pharma international

    Brochure

    Pharma international

    Sponsorship

    Pharma international

    India Pharma 2018 will cover all the sectors of the pharmaceutical industry starting from finished formulations, APIs, Bio-pharmaveuticals, Fine Chemicals and intermediates, Natural extracts, Excipients and many more.

    Display of Latest Pharmaceutical Machinery, Plants, Laboratory Equipment, Analytical Instrument and Cleanroom Equipments.

    Direct Access to Highly targeted Senior Pharma Executives, Buyers, Procurement Managers, Contract Manufacturers.

    • Pharma international
    • Pharma international
    • Pharma international
    • Pharma international
    • Pharma international




    Fachbereich Chemie, pharmazie.#Pharmazie

    Aktuelles – Fachbereich Chemie und Pharmazie

    Um seine herausragenden akademischen Beiträge im Bereich der elektrochemischen Energiespeicherung und Energiewandlung zu würdigen, hat die National Taiwan Tech University of Science and Technology (NTUST), Taiwan Tech, Martin Winter zum Ehrenprofessor ernannt. Die feierliche Verleihung wurde durch den Präsidenten der NTUST Prof. Ching-Jong Liao im Beisein von Martin Eberts, Generaldirektor des Deutschen Instituts in Taipei, der deutschen Auslandsvertretung in Taiwan, vorgenommen.

    Pharmazie

    Pharmazie

    Anlässlich des an der WWU Münster vom 28.09 bis 30.09.2017 stattfindenden Jahreskongresses der Deutschen Gesellschaft für Phytotherapie wurde Frau Dr. Verena Spiegler (Institut für Pharmazeutische Biologie und Phytochemie) durch die Präsidentin der Gesellschaft, Frau Prof. Dr. K. Kraft, mit dem Nachwuchsförderpreis für ihre wissenschaftliche Arbeit „Anthelmintic activity of procyanidins from West African plants: From traditional medicine to phytochemistry and molecular investigations“ ausgezeichnet. Der Preis ist mit 2.000 € dotiert.

    WWU-Professor Dr. Frank Glorius erhält Arthur C. Cope Scholar Award

    Pharmazie

    Pharmazie

    Große Ehre für Frank Glorius: Die American Chemical Society (ACS) zeichnet den Professor für Organische Chemie der Westfälischen Wilhelms-Universität Münster (WWU) mit einem Arthur C. Cope Scholar Award aus. Der Preis wird für hervorragende Leistungen in der Organischen Chemie vergeben und ist mit insgesamt 45.000 US-Dollar dotiert.

    Chemiker der Universität Münster entwickeln neues Verfahren zur Synthese von fluorierten Molekülringen

    Pharmazie

    Pharmazie

    Prof. Dr. Frank Glorius und Koautoren haben eine neue, einfache Methode zur Herstellung von bislang schwer herstellbaren Fluor-tragenden dreidimensionalen molekularen Ringstrukturen entwickelt. Da diese Verbindungen zum Beispiel eine groГџe Rolle bei der Entwicklung neuer Wirkstoffe haben, ist diese in “Science” verГ¶ffentlichte neue Methode von groГџer Bedeutung.

    Biochemiker beobachten Enzyme bei der Arbeit

    Pharmazie

    Pharmazie

    Forscher um den WWU-Biochemiker Prof. Dr. Henning Mootz haben neue Erkenntnisse Гјber das Zusammenspiel der verschiedenen Komponenten von Enzym-Apparaten vorgestellt, die in lebenden Zellen zur Produktion von Proteinen dienen. Die Studie ist in “Nature Chemical Biology” verГ¶ffentlicht.

    Nachwuchsforscher treffen Chemie-Nobelpreisträger

    Seit 67 Jahren bringt die Lindauer Nobelpreisträgertagung erfolgreiche Wissenschaftler und Nachwuchsforscher zusammen. In einem mehrstufigen internationalen Auswahlverfahren haben auch drei junge Chemiker der Universität Münster überzeugt: Dr. Emily Mackay, Felix Klauck und Matthias Elinkmann hatten interessante Begegnungen und Gespräche mit den Nobelpreisträgern und anderen Wissenschaftlern ihrer Generation.

    Chemie-Olympioniken zu Gast am Fachbereich

    Pharmazie

    Pharmazie

    10 SchГјlerinnen und -schГјler aus Gymnasien in Nordrhein-Westfalen, die besonders gut bei der 2. nationalen Runde der Internationalen Chemie-Olympiade 2017 abgeschnitten haben, erhielten einen Einblick in die Forschung der Pharmazeutische Biologie und Phytochemie. Die “Olympioniken” durften die einige Alkaloide aus pulverisiertem Opium herauslГ¶sen und bestimmten die Zusammensetzung des Alkaloid-Gemisches. Dabei durften Sie viele Verfahren kennen lernen, die nicht Bestandteile des Schullehrplans sind.

    Nachwuchspreis fГјr Dr. Fabian Dielmann

    Pharmazie

    Pharmazie

    Dr. Fabian Dielmann erhielt fГјr seine herausragenden Arbeiten zu Phosphanen am 20. Juni den diesjГ¤hrigen “Preis zur FГ¶rderung des wissenschaftlichen Nachwuchses” der UniversitГ¤tsgesellschaft der WestfГ¤lischen Wilhelms-UniversitГ¤t MГјnster. Durch die Entwicklung eines neuen, besonders elektronenreichen Typs von Phosphanen mit bemerkenswerten Eigenschaften leistete er einen elementaren Beitrag auf dem Gebiet der Synthesechemie. Der Preis, der von der Sparkasse MГјnsterland Ost an insgesamt drei PreistrГ¤ger gestiftet wurde, ist mit jeweils 5000 Euro dotiert.





    Global Lithium-Ion Battery Market: By Type, Application, Size, Share, Analysis and Forecast 2016 – 2022,

    Lithium-Ion Battery Market by Power Capacity Segment, Lithium-Ion Battery Market Has Been Segmented Into 5–25 WH, 48-95 WH, 18–28 KWH, 100–250 KWH And More Than 300 KWH for Include Automotive, Aerospace and Defense, Consumer Electronics, Industrial And Others Application – Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022

    Global lithium-ion battery market is expected to reach USD 67.70 billion by 2022, growing at a CAGR of 13.70% between 2017 and 2022.

    31-Aug-2017 | Number of pages: 110 | Report Code: ZMR-2165 | Report Format : | Status : Published

    The report covers forecast and analysis for the lithium-ion battery market on a global and regional level. The study gives historical data of the year 2014 to 2016 and forecast for 2017-2022 on the basis of revenue (USD Billion). The study includes drivers and restraints for the lithium-ion battery market. Additionally, the report includes the study of opportunities available in the lithium-ion battery market on a global level.

    In order to provide comprehensive coverage on the lithium-ion battery market, we have included analysis of Porter s Five Forces model for this market. The study includes a market attractiveness analysis, in which power capacity, application, and regional segments are assessed on the basis of their market size, general attractiveness, and growth rate.

    The report provides company market share analysis in order to give a broader overview of the key players in the market. Additionally, the report also covers strategic developments of the market including power capacity regional expansion, agreements, partnerships, collaborations joint ventures, acquisitions mergers, and research development, of major participants involved in the market on the global and regional level.

    The study provides a decisive view on the lithium-ion battery market by segmenting the market based on power capacity, application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East Africa for lithium-ion battery market. This segmentation includes demand for lithium-ion battery based on the individual segment in all the regions and countries.

    The competitive profiling of key players of lithium-ion battery market includes company and financial overview, business strategies adopted by them, their recent developments and power capacity offered by them which can help in assessing competition in the market. Key players operative in this market is Panasonic Corporation, Hitachi Chemical Co. Ltd., BAK Group , Johnson Controls, Inc., Samsung SDI Co. Ltd., LG Chem Power, Inc., Toshiba Corporation., A123 Systems, LLC., Saft Groupe SA , GS Yuasa Corporation , Automotive Energy Supply Corporation (AESC), BYD Company Ltd., Valence Technology, Inc. among others.

    This report segments the global lithium-ion battery market as follows:

    Global Lithium-Ion Battery Market: Application Segment Analysis





    Top 10 PCD Pharma Companies in India – 2017 List by Fossil Remedies, top ten

    List of Top 10 PCD Pharma Companies in India

    Top ten pharma companies

    Top 10 PCD Pharma Companies in India

    Fossil Remedies

    Having headquarters in Ahmadabad, Gujarat, ‘Fossil Remedies’ is the top most Pharma franchises company in India with long years of experience.They manufacture and market more than 2800+ Pharma products and indulge in 8 Special divisions . They offer franchise and PCD Pharma distributorships to interested parties.

    Some of their product ranges are:

    400+ Antibiotics and general products

    150+ Cardiac Diabetes Product

    150+ Skin Cosmetic Products

    100+ Gynec Hormones Products

    50+ Ophthalmology Products

    Fitwel Pharma

    Another leading Pharma company in Ahmadabad, Gujarat is ‘Fitwel Pharmaceuticals’. This company is awarded with ISO 9001:2008 for its high quality products ranging nearly 200.‘Fitwel Pharmaceuticals’ strongly follows affordable price, best quality, prompt delivery, innovative products , products availability and prompt settling of queries.

    Frank Medilink

    This Pharma Company in Ahmadabad, started in 2008, introduces itself as integrated franchise PCD Pharma Company.It started marketing to eastern part of India and then expended to other parts of India. This is also an ISO 9001:2008 certified company.

    Cubit Healthcare

    Cubit Healthcare is a integrated franchise (PCD) pharmaceutical company. It is a leading player in the franchise business in the country. It has a significant presence in brands across all therapeutic segment like from cough cold to life threatening serious diseases.

    Progressive Life Care

    As one of the leading Pharma companies in Gujarat that is in the top ten companies list, this company specializes in more than 200 life care products. They offer PCD Pharma franchises opportunities for marketing in its, own state and all through India.

    Ambit PCD Pharma

    Another top PCD Pharma company from Ahmadabad, Ambit PCD Pharma supplies quality prescription products from 2006 onwards. This ISO 9001:2008 company has WHO GMP certified plants through which they produce nearly 250 Pharma products.

    Radico Remedies

    This leading PCD Pharma Company is located in Baddi, Himachal Pradesh of India. With its 30 years of experience, they excel in producing excellent quality Pharma products in dermatology, neuro psychiatry, ophthalmology, veterinary and generics.

    Green Cross Remedies

    With 20 years of experience, this ISO certified PCD Pharma Company offers ethical based PCD Pharma franchise opportunity to dealers, distributors and medical representatives from all over India to get PCD Pharma Franchise with 100% monopoly.

    Tesni Pharma

    This ISO 9001-2008 Certified Company has WHO GMP certified plants through which they produce large amount of Pharma Products. At Tesni Pharma, we offer a highly profitable platform to the Pharma companies as well as to the investors who want to get into the PCD Pharma business.

    Zubit Lifecare

    Started in 2001 in Ahmadabad, Gujarat, this PCD company deals in more than 350 Pharma products.





    Find Pharmaceutical Jobs In Ireland, pharma it jobs.#Pharma #it #jobs

    Pharmaceutical Jobs

    Pharma it jobs

    WE ARE EXPANDING OUR TEAM

    EirGen Pharma is expanding and adding a second site locally in Waterford, as part of this growth we have a number of key positions which all come with a competitive salary and benefits package as well as opportunity to join an exciting global pharmaceutical company.

    To apply for any of the roles listed, or to obtain further information, email us at [email protected].

    When applying for any of these positions, please include your CV, a Covering Letter and clearly state for which Job Position you are applying.







    EirGen Job Opportunities

    Please click below for a recent advertisement which we recorded showcasing the opportunities that are currently open to interested candidates:

    In the event that the below links do not grant you access to apply, please forward your application to [email protected] mentioning the relevant position in your title.

    SENIOR MICROBIOLOGIST

    • Supporting production in our shiny new state of the art Sterile Fill Finish production suite
    • Coaching and training junior members of the Microbiology Team
    • Using lots of new high-tech equipment including our MaldiTof and Qube Isolator
    • Keeping abreast of new Microbiology trends and technologies
    • Getting hands on with all the Microbiology bugs!
    • You MUST be passionate about Microbiology (bug lovers wanted!)
    • A degree in Microbiology (or a related discipline)
    • You MUST have at least 5+ years’ Microbiology experience
    • Appreciate the importance of following SOPs and good GDP
    • Enjoy the coordination of tasks and management of workloads
    • Self-starter who enjoys working in a fast paced environment
    • You MUST enjoy working as part of a team and be fun and friendly

    Earn extra credit by meeting the following criteria:

    • Previous Sterile Fill Finish experience is a HUGE bonus
    • People management skills will also earn you additional points

    What will you get if you work with us?

    Aside from having a great day at work, you’ll also get:

    • A great work environment with lots of fun
    • A chance to work with like-minded people
    • Be part of a team of people who work together to make life-saving products
    • Work in Ireland’s Pharma Company (SME) of the Year
    • A great financial package to meet your knowledge and experience
    • A company contributed pension
    • Health Insurance
    • Extra day’s holidays
    • Company sponsored events and nights out
    • And lots of other stuff!!




    Global Pharmaceutical Database, Top 50 Pharmaceutical Companies, 5000 Contacts, Pharma Database, Pharma Companies, global pharmaceutical

    global pharmaceutical companies

    Global Pharmaceutical Database 2011 is the most current and up-to-date pharma database in the market. While there are many contact lists available on the internet, none of them are accurate and focused on illustrating business contacts from different strategic processes and key departments within the pharma industry. This database is greatly essential for marketers and sales professional who are stuck in their business development activities as they do not have valid and accurate information on their target contacts at the pharmaceutical industry.

    • Includes 5000+ contacts from the Top 50 pharma companies from around the world.
    • Includes primary contacts related to Market research, Sales, IT, Supply chain and Procurement, Finance, Human Resources, Clinical research, Oncology, Biomarkers and Quality.
    • Information includes name, designation, address, phone no. and working email.
    • Includes contacts from multiple company locations hence constituting a global database.
    • Detailed company profiles and executive bios available on request

    This database is extremely beneficial for:

    • Independent consulting houses targeting the pharma industry for market research and consulting
    • Supply and logistics companies who target the massive worldwide transportation and supply chain requirements of the pharma industry
    • Information technology and software firms who target the pharma companies to promote their CRM, MIS and ERP related products and services
    • Firms which deal in packaging material for pharma and healthcare markets.
    • Marketing and branding firms who are looking to cater to the huge potential of the pharma and biotech market.
    • Recruitment agencies and consultancies.
    • Chemical manufacturers that deal in pharmaceutical raw materials.

    This database was created using the best in practice primary research tools. An average 15 minutes are spent in collecting Intel of 1 contact. We have spent more than 1000 manual hours in building this accurate list of contacts. You save money and also a lot of time by using the Global Pharma Database 2010. By having this tailor made database you can now pump new life in your marketing and PR activities.

    For more information on the Global Pharmaceutical Database 2010 and to request free trial, please fill in the below form.





    Kamagra rezeptfrei online bestellen – original Kamagra, ajanta pharma kamagra.#Ajanta #pharma #kamagra

    Kamagra direkt online kaufen

    Ajanta pharma kamagra

    KamagraShop für original Kamagra Tabletten – Mit wenigen Klicks bestellen Sie Ihr Kamagra sicher SSL-geschützt bei uns im Shop. Die Kamagra Lieferung ist schon wenige Tage später bei Ihnen im Briefkasten. Ihr Kamagra kommt neutral verpackt und der Versand erfolgt garantiert aus der EU.

    Kamagra ist ein Potenzmittel, das bei Männern mit erektiler Dysfunktion helfen kann. Kamagra Tabletten enthalten 100mg Sildenafil Citrat, der gleiche Wirkstoff in exakt der gleichen Menge, der Viagra zu welweitem Ruhm verholfen hat. Kamagra sind normalerweise sehr gut verträglich und tausendfach bewährt.

    Ajanta pharma kamagraWas wir Ihnen senden (Kamagra Produktbilder)

    Ajanta pharma kamagraInfos zur Einnahme & Wirkung von Kamagra

    Kamagra jetzt bestellen

    Ihre Kamagra Bestellung wird innerhalb von zwei Tagen versandt und ist oft schon nach drei bis fünf Arbeitstagen bei Ihnen.

    Unser Tip: Jetzt 100 Kamagra Tabletten bestellen, wir legen 20 Tabletten umsonst dazu! Sie bekommen 120 Kamagra Tabletten für nur 189.99

    Kamagra Tabletten – Hinweise

    Unsere Kamagra Tabletten sind die höchste erhältliche Dosierung von 100mg Sildenafil. Die Farbe der Kamagra Tabletten ist türkis-grün, und nicht mehr blau wie noch bis vor etwa einem Jahr. Beachten Sie bitte das blaue Tabletten nicht mehr die Orginalware aus Indien sind. Die Farbe wurde aufgrund eines Rechtsstreits mit dem Hersteller von Viagra geändert.

    Wir empfehlen eine Kamagra Tablette etwa 30 bis 45 Minuten vor dem Sex einzunehmen. Die Wirkung setzt nach etwa 30 Minuten ein und hält bis zu drei Stunden an. Falls Sie vor der Einnahme der Kamagra Tablette reichlich gegessen haben kann die Wirkung verzögert eintreten, und etwas schwächer sein, das das Essen im Magen die Aufnahme des Wirkstoffs verhindert. Kamagra Tabletten helfen Ihnen zur Erektion wenn Sie sexuell erregt sind, erzeugen aber von sich aus keine Erektion.

    Sie können die Kamagra Tabletten halbieren um zwei Einheiten mit jeweils 50mg Wirkstoff zu erhalten. Nehmen Sie nicht mehr als eine Tablette alle 24 Stunden.

    Kamagra wird nach höchstem medizinischen Standard in Indien von Ajanta Pharma gefertigt. Alle Kamagra Tabletten werden in orginal Blistern geliefert, auf den Herstelldatum, Hersteller und das Ablaufdatum aufgedruckt sind.

    Kamagra Shop Deutschland – Der Kamagra und Generika Shop 2017

    Ajanta pharma kamagra

    Bewerten Sie uns bitte auf Ajanta pharma kamagra – Gelistet auf kuio.de

    Ajanta pharma kamagra

    Ajanta pharma kamagra





    Medzilla; Biotech Jobs, Pharmaceutical Jobs, Pharmaceutical Sales Jobs, Resumes, Medical Career, Job Board, Biopharmaceutical Jobs,

    MedZilla

    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs

    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs
    • Pharma it jobs

    This Week’s Featured Jobs

    Opportunity posted by Sunrise Systems Inc

    Opportunity posted by Sunrise Systems Inc

    Opportunity posted by Takeda Pharmaceuticals

    Opportunity posted by PDI, Inc

    Opportunity posted by Novartis

    Opportunity posted by Touchpoint Solutions

    Opportunity posted by Lundbeck

    Opportunity posted by inVentiv Health

    Opportunity posted by Novo Nordisk

    Opportunity posted by PDI, Inc

    View our Newest Jobs by State

    View our Newest Jobs by Profession

    Employers & Recruiters

    Search now, thank us later:

    Search our pre-screened candidates for the talents you need now for FREE!

    – Mark S, Sales Executive

    – James D, Lab Technichian

    – T. Baker, University of Florida

    – K. Dalton, Clinical Director

    – S. Ohlinger, Pharmaceutical Sales Rep

    – Thom B, ETS Systems

    Job Seekers

    Post your resume to become Medzilla Certified and start getting job offers NOW!

    Post your Resume

    Hot Topics on Our Forums

    ICON offers up to 7K per calendar year for tuition reimbursement. Eligibility begins the 1st of the following month after date of hire.

    Just wonder what CRO provide tuition reimbursement or yearly allowance for school. I am not asking about PMP or ACRP fees for exams etc. This would be for some one that wants to get their MBA, law degree etc.

    Looking for advice from those who are in pharma Sales or recruit for pharma sales. I have always been interested in sales and at the same time I was applying to graduate schools for my teaching certificate, I was also applying to pharma. companies . Read More

    Latest Articles

    The MedZilla.com Employment Report: Permanent R ?>

    Home – Helix Recruitment – Helix Recruitment, helix pharma.#Helix #pharma

    Helix pharma

    We recruit technically skilled and commercially astute people into customer facing roles for Healthcare and Scientific companies.

    From start-ups to global organisations, our clients provide products for Clinical Pathology, Analytical Science, Life Science, Biotech and Environmental markets.

    We partner Medical Device, Healthcare IT and Services companies, including capital equipment, disposable and specialist pharma products.

    Healthcare Scientific Recruitment Specialists

    Sales – Marketing – Clinical Applications Support – Engineering

    Healthcare

    Scientific

    Send Us Your CV

    1. Featured Jobs
    2. Latest Jobs

    Permanent Part Time Healthcare

    Why Helix?

    Working with Helix means talking to enthusiastic specialists; we understand the job seekers, the companies, and the options available in your market.

    We take time to listen to our clients and candidates, so when we match people to jobs and jobs to people, we’re not just matching experience; we’re taking into account what each candidate is looking for from a career move in order to feel fulfilled, appreciated and on a career path that is right for them. By taking this approach we ensure our clients are only presented with a small number of relevant, interested and career focused job seekers who want to stay and grow with the company over many years.

    Rather than selling jobs to candidates / candidates to clients, we focus our efforts on fully understanding our client’s and candidate’s criteria in order to present options that sell themselves – as we source what you’re looking for. Our approach has won us preferred supplier agreements with some of the biggest and brightest companies out there, leading to loyal relationships with hiring teams who trust our methods and standards.





    Pharma Bro – Martin Shkreli has bail revoked, heads to jail after Facebook post about

    ‘Pharma Bro’ Martin Shkreli has bail revoked, heads to jail after Facebook post about Hillary Clinton’s hair

    Former pharmaceuticals company CEO Martin Shkreli has had his bail revoked and is going to jail in New York while he awaits sentencing for a securities fraud conviction.

    Former pharmaceuticals company CEO Martin Shkreli has had his bail revoked and is going to jail in New York while he awaits sentencing for a securities fraud conviction.

    A judge jailed former pharmaceuticals company CEO Martin Shkreli on Wednesday after finding that he violated his bail on a securities fraud conviction with a social media posting she agreed posed a threat to Hillary Clinton.

    Defense attorneys had argued at a hearing in federal court in Brooklyn that the post by Shkreli, offering a $5,000 bounty to anyone who could grab him one of Clinton’s hairs while she’s on a book tour, was political satire. But U.S. District Judge Kiyo Matsumoto didn’t see the humor, saying the offer could be taken seriously by fellow Clinton detractors.

    The Clinton offer could be viewed as a solicitation of an assault, the judge said before revoking Shkreli’s $5 million bail.

    This is not protected by the First Amendment, the judge said. . There’s a risk that somebody may take him up on it.

    The government had told the judge that the message had alarmed the Secret Service detail that protects Clinton, a Democratic former presidential candidate and first lady. It also argued that it fit a pattern of veiled threats against female journalists who rebuffed Shkreli’s social media advances and of taunts aimed at prosecutors in his case.

    On Wednesday morning, Shkreli, often called the Pharma Bro, wrote to the court apologizing for his behavior, saying, I am not a violent person.

    But for the judge, it was too little, too late.

    He doesn’t have to apologize to me, she said. He should apologize to the government, the Secret Service and Hillary Clinton.

    The out-of-court antics of Martin Shkreli, the former hedge fund manager convicted of defrauding his investors, may finally be coming back to haunt him.

    A federal judge on Wednesday is scheduled to hold a hearing on whether to revoke Shkreli’s $5 million bond after prosecutors complained that he.

    The out-of-court antics of Martin Shkreli, the former hedge fund manager convicted of defrauding his investors, may finally be coming back to haunt him.

    A federal judge on Wednesday is scheduled to hold a hearing on whether to revoke Shkreli’s $5 million bond after prosecutors complained that he.

    Shkreli watched in silence as the hearing unfolded and sometimes put his head down and appeared to scribble notes. After the judge’s ruling, he remained expressionless as deputy U.S. marshals led him out a side door of the courtroom without handcuffing him.

    The government sought to get Shkreli locked up as a danger to the community amid the fallout from his social media post, which read: The Clinton Foundation is willing to KILL to protect its secrets. So on HRC’s book tour, try to grab a hair from her. I must confirm the sequences I have. Will pay $5,000 per hair obtained from Hillary Clinton.

    The defense insisted it was merely a tasteless joke comparable to some of President Donald Trump’s derisive comments.

    Indeed, in the current political climate, dissent has unfortunately often taken the form of political satire, hyperbole, parody or sarcasm, the defense’s court papers said. There is a difference, however, between comments that are intended to threaten or harass and comments — albeit offensive ones — that are intended as political satire or strained humor.

    Shkreli, who is best known for hiking up the price of a life-saving drug and for trolling his critics on social media, was found guilty last month on charges, unrelated to the price-fixing scandal, that he cheated investors in two failed hedge funds he ran. The defense had argued that investors got their original investments back and even made hefty profits.

    Shkreli faces up to 20 years in prison at sentencing, set for Jan. 16.





    Pharma international, pharma international.#Pharma #international

    Pharma international

    • Pharma international

  • Pharma international

  • Pharma international

  • Pharma international

  • Pharma international

    pharma.be

    En tant que partenaire à part entière des médecins, pharmaciens, hôpitaux, autorités et autres partenaires de la santé, pharma.be a pour mission de promouvoir les meilleurs soins de santé en encourageant l’innovation thérapeutique dans le domaine des médicaments à usage humain. Sa priorité absolue est donc de permettre aux patients un accès le plus rapide possible aux traitements les plus récents, issus de la Recherche et du Développement.

    • 6 novembre 2017

    Offre d’emploi : Expert en Communication chez pharma.be

    En vue de renforcer son équipe Communication, pharma.be est à la recherche d’un communicateur de terrain (M/F) à la plume facile et versé dans la communication via les médias sociaux. Une expérience de minimum 2 ans dans le secteur de la santé ou socio-économique est souhaitée. Une expérience dans le secteur biopharmaceutique constitue un plus. Nous recherchons un candidat parfaitement trilingue français-néerlandais-anglais. Lire la suite

    Davy Persoons (pharma.be) : « Une approche durable en Belgique pour réduire l’utilisation d’antibiotiques chez les animaux »

    Davy Persoons, Animal Health Coordinator chez pharma.be, réagit aux chiffres de BelVetSAC 2016, un rapport annuel de la Faculté de médecine vétérinaire de l’Université de Gand, qui analyse l’utilisation d’antibiotiques chez les animaux en Belgique. Lire la suite

    Dr Herbert Ossemann (Prodivet – entreprise familiale) « En matière de santé animale, il faut agir avec mesure et responsabilité »

    Une rencontre avec le Docteur Herbert Ossemann, directeur général Prodivet Pharmaceuticals. Lire la suite





  • India Pharma 2018, 3rd International Exhibition And Conference On Pharmaceutical Industry, Conference, Event, B2B, Bengaluru

    pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    Pharma international

    • Host State Pharma international
    • Event Patron Pharma international
    • Principal Sponsor Pharma international
    • Principal Sponsor Pharma international
    • Co-Sponsor Pharma international
    • Associate Sponsor Pharma international
    • Regitration Counter Sponsor Pharma international
    • Gate Sponsor Pharma international
    • Strategic Partner Pharma international
    • Strategic Partner Pharma international
    • Supporting Association Pharma international

    Major event to increase overall growth of Pharma sector including exports and focus on increase of Domestic production in the sector by Government of India & FICCI, with the active participation from all Stakeholders.

    Provide a platform to global investment community to connect with stakeholders in Pharma sector in India, Central and State Governments, leading business leaders and top executives from the industry, academics and experts from the world.

    Encourage ‘Make in India’- for manufacturing of Drugs and Pharmaceutical Machines.

    INDIA PHARMA 2018 covers the whole process of Pharmaceutical Manufacturing, from various kind of manufacturing/processing machineries to Lab Equipment, Analytical Instruments, APIs and other total solutions.

    Pharma international

    Post Show Report

    Pharma international

    Floor Plan

    Pharma international

    Brochure

    Pharma international

    Sponsorship

    Pharma international

    India Pharma 2018 will cover all the sectors of the pharmaceutical industry starting from finished formulations, APIs, Bio-pharmaveuticals, Fine Chemicals and intermediates, Natural extracts, Excipients and many more.

    Display of Latest Pharmaceutical Machinery, Plants, Laboratory Equipment, Analytical Instrument and Cleanroom Equipments.

    Direct Access to Highly targeted Senior Pharma Executives, Buyers, Procurement Managers, Contract Manufacturers.

    • Pharma international
    • Pharma international
    • Pharma international
    • Pharma international
    • Pharma international




    5 Terrible Secrets Big Drug Companies Don t Want You to Know, top drug companies.#Top

    5 Terrible Secrets Big Drug Companies Don t Want You to Know

    Top drug companies

    6 Normal People Who Became Crazy Badasses When Facing Danger

    Top drug companies

    The 13 Most Insane Things Happening Right Now (11/22/16)

    12 Fetishes That Will Brighten Your Day

    If you go by their portrayal in movies and TV shows, you’d think that huge pharmaceutical corporations make all their money by turning children into zombies and having them steal grandma’s heart medication, or whatever the plot of Resident Evil was. But the truth is that Big Pharma (as hippies and crackpots call it) isn’t a modern-day Legion of Doom. They’re businesses focused on making money, just like every other company out there . which isn’t to say they aren’t capable of evil. They totally are. It’s just that their evil usually involves less illegal genetic experiments and more down-to-earth dick moves like .

    Advertisement

    The name of a drug is a crucial part of its marketing. The antidepressant Prozac, for example, is meant to sound sciency, while the drug Sarafem, which is targeted at women, sounds distinctly feminine. (It’s also pink, because . vaginas, we suppose?) However, the only differences between these supposedly very different drugs are their names and colors: Sarafem is actually just Prozac, because Eli Lilly, the drug company behind both medications, wanted women to take the drug without telling them what it was.

    Top drug companiesWarner Chilcott/Eli Lilly

    “But it says ‘fluoxetine’ right on the label. How can you not immediately know what that is?!”

    Advertisement

    Read Next

    Pepsi Releases New Salted Caramel Flavor. Uh, You Ok Guys?

    Sarafem was marketed as the cure for an ailment called premenstrual dysphoric disorder — essentially, all the unpleasantness that goes along with menstruation, plus horrible panic attacks, anxiety, and souped-up mood swings. And we’re not saying that Prozac doesn’t treat those symptoms; it might (we’re not doctors). We just think that tricking people into taking drugs they wouldn’t otherwise take is a moral gray area, although it could be forgiven if it was done for noble intentions. Like, say, if women suffering from PMDD really needed to take Prozac but were avoiding it due to its negative association with depression. That, however, is not what happened here.

    Advertisement

    Prozac was a huge money maker for Eli Lilly, and Sarafem was released only a few months before their patent on Prozac was set to expire. When a drug patent expires, its price drops sharply, as competitors start releasing their own generic versions. But by releasing a new drug identical to Prozac, Eli Lilly managed to extend their patent by a few years, allowing the price of Prozac to remain nice and high.

    Top drug companiesHemera Technologies/AbleStock.com/Getty Images

    Depressing, huh? Don’t worry — Eli Lilly has the cure!

    Advertisement

    In 1997, GlaxoSmithKline did something similar when they released the well-known antidepressant Wellbutrin as a pill that helps you quit smoking, but only after rebranding it as Zyban. Again, the science behind the drug might have actually been sound, but it doesn’t change the fact that deceiving people into taking mind-altering drugs is something you usually expect to end with James Bond blowing up a skull-shaped island fortress in the middle of the Pacific.

    All right, so how exactly do doctors know what medication to give you, when new stuff is coming out all the time?

    Advertisement

    Well, they read medical journals, which are full of studies telling them what’s working these days. Unfortunately, pharmaceutical companies know that, so when they roll out a new product that they know occasionally gives patients uncontrollable diarrhea, they first release an overwhelming number of falsified studies that replace the word “diarrhea” with “kittens.”

    Top drug companiesCherry-Merry/iStock/Getty Images

    The kittens have diarrhea, but it’s adorable.

    Advertisement

    OK, the actual practice is a little more subtle than the kitten thing. In one real case, drug company Medtronic paid $210 million to dozens of surgeons to sign their names to medical articles that were drafted and edited with the help of Medtronic marketers to advertise the company’s bone-growth product Infuse . the same Infuse that was later linked to cancer and infertility in men, which might have affected any of the million people who were prescribed it. The warnings were always there in the fine print, but the marketers were able to tweak the wording to play up the benefits and brush off the horrifying risks and side effects. The authors who went along with it could later be seen wearing lab coats made of solid gold.

    Advertisement

    But even when drug companies go to the effort of conducting genuine scientific studies, oftentimes they simply don’t publish the unfavorable results. In one experiment, a number of studies of an antidepressant medication were submitted to a drug regulatory authority, and in the end, only the studies that yielded favorable results were released to the public. Oh, did we forget to mention that the studies were funded by huge pharmaceutical conglomerates? This is why some researchers believe that the vast majority of studies on antidepressants are unreliable at best and complete horseshit at worst.

    Personally, we prefer the trial-and-error method.

    But what about independent studies that aren’t paid for by big businesses? Sure, they exist, but many of the researchers end up getting sued, and the studies are kept from publication by the drug company lawyers. Remember, the companies don’t even need to win their suits — all they need to do is keep bringing the scientists back to court until they run out of money and resort to burning their research notes for warmth.

    Advertisement

    Advertisement

    Other than medical journals, the other way for doctors to stay informed about drugs is through sales reps, who visit medical professionals and tell them about the newest pill-magic their company has come up with. Sales representative visits are basically the medical education equivalent of a pizza delivery in a porno, by which we mean that they are quick and convenient and usually end with someone getting fucked. The bad news? That someone is usually us.

    “On the plus side, we’ve got plenty of birth control options for you to use while we do it.”

    Advertisement

    In most countries, drug sales reps are legally required to disclose all relevant information about a drug they are promoting to the doctor, not just the fun stuff. But in the U.S., Canada, and France, it’s been found that they only mention serious drug risks 6 percent of the time. Because, you know, they’re in sales. Their goal isn’t to inform; their goal is to get the doctors to sign on the dotted line — and your doctor is just as susceptible to slick sales techniques as anybody else.

    So what’s the risk here? Well, more than half of the drugs whose downsides aren’t mentioned carry the most severe warning that can be issued — we’re talking “may cause death” territory here. And that’s just for the risks — things that might go horribly wrong when someone takes the drug. This is not to be confused with side effects, which are things that will almost definitely go horribly right if you take the drug. But again, sales reps won’t even mention side effects in 59 percent of the cases.

    “When you think about it, what is ‘anal bleeding’ really?”

    Advertisement

    Part of the problem is that some hospitals might be greeting over a dozen sales reps a day. The doctors want to listen just long enough to get the merchandise and free samples, but not a moment longer than they have to. This leads to super condensed sales pitches, and if something’s going to get cut, it’ll be the downsides. A far larger part of the problem, however, is that despite the law being pretty clear on these points, there’s practically no oversight or enforcement of it whatsoever.





    PharmaVOICE – READ, pharma agency.#Pharma #agency

    Get your free subscription to PharmaVOICE Magazine

    Click one of the links below to pick what type of subscription you’d like. It’s completely free.

    Already subscribed?

    Click here to login

    Have a Question?

    Email Customer Service

    Remember your password?

    Click here to login.

    Have a Question?

    Contact Customer Service

    Pharma agency

    Read the Digital Edition

    Pharma agency

    FEATURED CONTRIBUTED CONTENT

    Pharma agency

    Evidera’s biannual publication addresses the scientific, strategic, and operational challenges of today’s healthcare environment, providing a forum for the exchange of thoughts and ideas focused on evidence and value. This issue is focused on Redefining Drug Development, highlighting the latest changes to regulations and guidelines, exploring the evolving needs in real-world and patient-centered evidence, and [ ]

    Pharma agency

    The emergence of digital pathology presents an opportunity for central laboratories to support highly targeted therapeutics and precision medicine even further, offering many advantages to both diagnostic and clinical trials testing. This paper explains the noteworthy progress in the industry’s wider acceptance of digital pathology systems and its many benefits. There is also a related [ ]

    Pharma agency

    Ensuring a patient-first strategy drives real results in commercial pharma Does patient centricity work? Actually, yes. There are increasing volumes of evidence that demonstrate that when you focus on the difference you make to patients, your commercial performance will improve. And, as other stakeholders adapt to the same economic conditions, driven by data and our ability to measure [ ]

    Pharma agency

    Are you looking for a new opportunity? MicroMass Communications are behavior change specialists. Everyone from their writers to web developers plays a key role in developing solutions that have a powerful impact on the patients and providers they reach. Their collaborative culture, values, and emphasis on training and growth (not to mention their beer fridge) [ ]

    Pharma agency

    Ever wonder why 80% of clinical trials are delayed? The top reason is unfulfilled enrollment, and there are specific reasons why this happens with so many trials This webinar will reveal 5 patient enrollment errors that stall enrollment timelines in trial after trial. More importantly, it will provide useful advice, based on proven methods, for [ ]

    Pharma agency

    In the life science industry, demand is exploding for evidence generated through real-world data. Unfortunately, most companies haven’t significantly updated their methods for generating evidence in the past 25 years. Are you ready to handle the disruption? This ebook covers numerous issues from a variety of stakeholders, including data visualization capabilities, advanced analytics, rich data [ ]

    Pharma agency

    Author: Marc Benjamin, CEO, Convergence Point Media Pharma marketing can sometimes feel like a thankless job, with the web of overlapping indications, “second plus”-line treatments, FDA regulations and privacy landmines sapping the joy out of even seasoned industry veterans. Even when you’ve seemingly overcome these obstacles and launched what you believed to be a campaign that [ ]

    Pharma agency

    In this episode, Dr. Matthew Turner talks about trends in Digital Pathology, and how this new research tool can benefit sponsors, CROs, and Pathologists. There is also a related white paper, entitled, How Digital Pathology is Revolutionizing Clinical Trials, which you can download using the link below.

    Pharma agency

    In the November issue of The Evidence Forum, one of the informative articles covers patient engagement and retention, two key issues in clinical studies. We’ve all heard the buzz about patient-centricity. In this article, learn how a patient-centric approach can improve patient engagement and retention. Here is a sample of what you will see in [ ]

    Pharma agency

    How Properly Timed, Targeted Engagement Tactics can Increase Adherence and Brand Revenue Co-pay savings programs are powerful brand marketing tools; not just because of their ability to introduce new patients to therapy, but also due to the wealth of patient behavior data that they generate. These data, when used properly, can drive targeted patient engagement strategies that are uniquely [ ]

    Pharma agency

    The term customer experience (CX) might be relatively new in pharma but the reality is as old as the industry itself. Every time a company interacts with a customer, it is delivering some sort of customer experience. In our increasingly multi-stakeholder and multichannel world, pharma companies must get comfortable with the idea that CX is not a linear, [ ]

    Pharma agency

    New Manatt Health Webinar Reveals the Megatrends Reinventing the Ways Your Patient, Provider and Payer Customers Think—and How You Should Respond to Succeed. Click to Register Free. From the continued evolution of new payment models to the explosion of mHealth to the creation of personalized therapies, powerful trends and disruptive innovations are converging to reshape [ ]

    Pharma agency

    One in three people will be diagnosed with cancer in their lifetime, but according to the NIH, only 3-5% of adult cancer patients participate in clinical trials. Advancing therapies in oncology and other disease areas is at the forefront of academic and commercial R D. But enrollment and site initiation is often hindered by daunting, time [ ]

    Pharma agency

    Drug development costs for Central Nervous System (CNS) trials are more complex and costly for pharmaceutical companies and often take longer to develop than other medicines. Failed studies often occur later in development when costs are the highest. For compound efficacy and safety that is being measured with electroencephalography (EEG), technical and recording difficulties simply [ ]





    INTERNATIONAL JOURNAL OF PHARMA SCIENCES AND RESEARCH (IJPSR), pharma international.#Pharma #international

    INTERNATIONAL JOURNAL OF PHARMA SCIENCES AND RESEARCH

    Pharma international

    Pharma international

    About IJPSR

    International Journal of Pharma Sciences and Research (IJPSR) is a non-profit making scientific electronic journal, publishing research and review articles, together with case studies, in the fields of Pharmaceutical Sciences and research. International Journal of Pharma Sciences and Research (IJPSR) is published monthly. International Journal of Pharma Sciences and Research (IJPSR) also publishes editorials, a letter to the editor section, surveys, and can function as an open discussion forum on significant issues of current interest. The journal content could be presented not only in print (pdf format) since it is published in an electronic format. Authors, therefore, are encouraged to submit their article or communication in the most appropriate medium to best convey their findings to members of International Journal of Pharma Sciences and Research (IJPSR).

    International Journal of Pharma Sciences and Research (IJPSR) is a scholarly open access, peer reviewed international journal with a primary objective to provide the academic community and industry for the submission of half of original research and applications related to Pharmaceutical Sciences. International Journal of Pharma Sciences and Research (IJPSR) mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences.

    Why One Should Publish With IJPSR:

    • Hassle Free Submission
    • Easy Tracking of Your Submitted Manuscript
    • Go-Getter Publication
    • Fast Processing Reviewing
    • Transparent Review Reporton Request
    • Easy access to the Content and Index

    Frequency: 12 issues per year

    Subject Category: Pharmaceutical Science

    Journal Title : International Journal of Pharma Sciences and Research (IJPSR)





    IMS 2015 Use of Medicines report: US sales reach $424, ims data pharma.#Ims #data #pharma

    Ims data pharmaIms data pharma

    Ims data pharma

    Ims data pharma

    Ims data pharma

    IMS 2015 Use of Medicines report: US sales reach $424.8 billion

    Double-digit growth (12.2%) for the second year running

    The annual Use of Medicines report, from the IMS Institute for Healthcare Informatics, comes at a time when drug pricing and revenue growth has been under intensive stress. Perhaps in part for this reason, the Institute is much more careful about distinguishing between ex-manufacturer invoice pricing (which is essentially the price that wholesalers charge their customers) and what it calls “net-price spending,” which accounts for the tens of billions of dollars that pharma companies forgo through rebates, discounts and other off-invoice concessions. Using invoice sales is a good way to track revenue trends from year to year (since discounting occurs at many times and in many different ways), but net-pricing reflects the revenue that manufacturers ultimately receive.

    So, the invoice sales of $424.8 billion recorded for 2015 translates, by IMS estimates, into $309.5 billion, and the year-over-year growth rate was 8.5%.

    Ims data pharmaSales by channel (Fig. 1) shows a reversal of a usual pattern: chain drug sales rose more slowly than independent pharmacies. And, even though mail order processed fewer prescriptions in 2015, it recorded the highest growth of any of the retail channels, reflecting the concentration in specialty pharmaceutical dispensing.

    Specialty products represented $150.4 billion of the 2015 invoice sales, up 21.6% over the previous year. New oncology products drove a good part of this growth; oncolytics alone represent invoice sales of $39.1 billion, up 18.1%. The new hepatitis C therapies—which seemed to kick off the current focus on drug pricing when Gilead Sciences generated over $10 billion in sales in its first full year on the market (2014), were used on nearly 250,000 patients in 2015; the Institute notes that new patient starts for hep C treatments is moderating.

    Ims data pharmaTotal prescription volume reached 4.368 billion (Fig. 2), an increase of 1.0% over the previous year. A distinct downturn in mail-order prescription fulfillment was found, which the Institute attributes to more off-patent medicines being filled at local pharmacies rather than through the mail. (Another factor here could be the shared dispensing now occurring between CVS Health’s Caremark PBM, which primarily employs mail order, and the CVS community pharmacy network; similar arrangements are occurring with other PBMs and pharmacies.)

    The Institute forecasts that revenue growth will reach $610-640 billion by 2020 (invoice basis). The Institute expects that approvals of New Active Substances by FDA to continue at a pace of 43–49 per year, which is roughly double the rate that was seen in the early 2010s.

    Drug pricing is unquestionably one of the hot buttons of the current political season; it should give pause to the pharma industry that most of the leading candidates have brought up re-importation (drugs purchased outside the US, but often originally manufactured and shipped from the US) and Medicare price negotiating as measures to control drug costs. A study from the Office of the Assistant Secretary for Planning and Evaluation (ASPE) in March calculated a “spending figure” of $457 billion for a combination of “retail” and “non-retail” drugs (the latter mostly being drugs purchased under a medical benefit and not via a prescription). Michael Kleinrock, research director at the IMS Institute, notes that the ASPE figures include hardly any of the rebates and other discounts that manufacturers provide to buyers; “it’s essentially what’s paid at the end of the supply chain, and not what manufacturers receive,” he says.

    IMS Institute is steadily refining its analysis of drug discounting, but Kleinrock notes that “drug pricing is not transparent” either to buyers, government or, ultimately, patients themselves. That transparency issue could be the starting point for the discussions when a new President is

    The full report is available from IMS Institute.





    Overdose Now Leads in Cause of Death, Proving Big Pharma s Opioids the Drug War

    Featured

    Crazy Gun Grabbing Mom Wants You To Ruin Thanksgiving By Talking About Gun Storage

    FDA, DEA Running Massive Conspiracy To Criminalize Kratom In Order To Protect Big Pharma s Obscene Opioid Profits

    What is big pharma

    What is big pharma

    What is big pharma

    Judge Protects Fmr House Speaker and Admitted Child Rapist, Telling His Victim He Can’t Sue

    Don’t Just Give Thanks. Pay It Forward One Act of Kindness at a Time

    OECD Data Suggests Dangerous Divisions in Developed World (Video)

    Daring Defector: Watch Brave North Korean Cross Border to Freedom Under Gunfire

    Google’s Eric Schmidt Says Americans Too Dumb To Detect Fake News, Plans to “Derank” Russian News

    Opioids Are Mind-Control Drugs; MKULTRA Is Alive and Well

    UNSEALED: Fusion GPS Bank Records Show Russia-Related Payments

    Video Proof: Eyewitnesses Claim Helicopters Were Used During Las Vegas Massacre

    Don t Try This At Home: Flat-Earther Plans A MANNED Launch Of Homemade Rocket

    Ron Paul: Why Are We Helping Saudi Arabia Destroy Yemen?

    Faces Of Evil: Bill Clinton, Al Franken, Charlie Rose And Glenn Thrush All Face New Sexual Misconduct Allegations

    FLASHBACK: Japan Said It Would Take One Million Men 100 Years To Take This Fortified Atoll, A Few Thousand US Marines Did It In Three Days

    FCC Unveils Plan To Roll Back Net Neutrality Rules

    The CIA Documented Long-Range Planning For A Drugged And Debilitated Society: Opioids Are Perfect Fit

    A Mysterious 3,000-Year-Old Castle Was Discovered Underwater In A Turkish Lake

    Report: Deep State Planning False Flag Cyber Attack To Blame On Russia

    Insane Dashcam Footage Shows a Suspected Drunk Driver Almost Slaughter Five People at High Speed

    Hackers Attack Sacramento Transit System for 1 BTC Ransom

    Amazon Launches Secret Region Cloud Service for US Intel Agencies

    Students Test Scores Plunge As Billions Poured Into Broken Education System

    Overdose Now Leads in Cause of Death, Proving Big Pharma s Opioids the Drug War s Winners

    June 7, 2017 | Claire Bernish | The Daily Sheeple | 1,230 views

    What is big pharma

    What is big pharma

    Drug overdoses kill more people under the age of 50 in the United States than anything else — more than vehicle crashes, homicide, gun-related incidents — anything.

    Unsurprisingly, more of those overdoses pertained to opioids — legal, prescription medications, or illicit heroin, too frequently of dubious quality, sought by those for whom State-sanctioned painkillers no longer killed the pain — than to any other substance.

    “To put the death toll into perspective,” Democracy Now! reports , “opioid deaths have now surpassed the peak in death by car crash in 1972, AIDS deaths in 1995 and gun deaths in 1993. After 20 years of heavy combat in South Vietnam, U.S. military casualties represented only one-third of the death toll from 10 years of opioid overdoses. Meanwhile, counties and states around the country have filed lawsuits to hold pharmaceutical companies accountable for the public health crisis.”

    Were it considered a contagious disease, the wildfire plague of opioid abuse and addiction would be pandemic.

    “The United States is in the midst of the worst drug addiction epidemic in its history,” Dr. Andrew Kolodny, co-director of opioid policy research at the Heller School for Social Policy and Management at Brandeis University, told journalist Amy Goodman in an interview. “And when I say that, I’m referring to the number of people who are addicted and the number of people dying from overdose deaths. The epidemic isn’t new. It began 20 years ago and has gotten worse every year steadily.”

    Over half the 52,000 people who succumbed to substance overdoses in 2015, according to the Department of Justice, did so using opioid medications, heroin, synthetic fentanyl, or other opioids.

    As if the crisis weren’t a horrendous in its own right, experts warned an astronomical uptick in overdose fatalities within just the past few years portends the epidemic is now mushrooming out of control.

    Prior to the invasion of Afghanistan by the United States in 2001, the Taliban had veritably eradicated the nation’s opium poppy supply — the Afghan yield had plummeted to just 185 tons that year.

    Before dust from American boots had time to settle, production was booming — indicators of the coming stateside crisis cropped up with increasing urgency in successive years.

    “Within six months of the U.S. invasion,” wrote Matthieu Aikins for the December 4, 2014, Rolling Stone , “the warlords we backed were running the opium trade, and the spring of 2002 saw a bumper harvest of 3,400 tons.”

    By around 2011 — with Afghanistan still shredded by U.S. interventionism, but now rich in proceeds from the opium poppy — the opioid epidemic plaguing American lives could no longer be dismissed as aberrant. Dr. Kolodny continues ,

    “We have two groups of Americans who have become opioid-addicted over the past 20 years: an older group and a younger group. The older group are people in their forties up through their eighties. Their addiction has developed really almost entirely from medical use of opioids. And the older group has been overdosing on prescription opioids. The younger group, people mostly in their twenties and thirties, are developing their opioid addiction also from prescription opioids, that were used either medically or recreationally or sometimes a combination of both. The younger folks, when they become addicted, they have a hard time maintaining their supply of opioids visiting doctors. And it isn’t that doctors or dentists don’t like to give young people opioids. Unfortunately, we’re pretty comfortable, too comfortable, doing that.

    “But doctors don’t like to give healthy-looking 25-year-olds a large quantity on a monthly basis. So, this younger group, when they become addicted, to maintain their supply, they wind up on the black market. The prescription opioids are very expensive on the black market, so they’ve been switching to heroin. And this switching began, you know, 20 years ago.”

    Of course, what isn’t often mentioned in mainstream media when the pernicious crisis does make headlines are several viable ways to rein it in — likely due to stigma and arbitrary laws.

    Kratom, a plant whose effects can mimic heroin and other opiates without its inherent dangers, shows promise in treating addiction through replacement therapy — granting the user a means to gradually wean themselves and reduce intake.

    Cannabis provides perhaps the greatest hope for addicts and abusers by supplanting opioids and treating pain — without any of the addictive qualities fueling the crisis to begin with.

    But because cannabis remains a Schedule I prohibited substance, still tainted with politicized stigmatization from fabricated propaganda of the war on drugs, those who could benefit heartily from the miracle weed aren’t able to do so unless they reside in one of the states with laxer laws.

    As long as the drug war unironically remains the U.S. government’s premier concern, the opioid epidemic cannot be contained.

    When an administration ultimately decides to put the public health instead of arbitrary legality as its number one priority — which would include an unhindered discussion about viable solutions — then, and only then, will the pharmaceutical industry finally be condemned for the deception and profiteering at the heart of the crisis.

    We encourage you to share and republish our reports, analyses, breaking news and videos (Click for details).

    Claire Bernish is a staff writer and reporter for The Daily Sheeple. Wake the flock up follow Claire s work at our Facebook or Twitter.





    Farmacie Online Chisinau, intas pharma.#Intas #pharma

    intas pharma

    Intas pharma

    Intas pharma Intas pharma

    Intas pharma

    Intas pharma

    Pe categorii

    Cauta medicament

    Farmacie Online Chişinău

    Farmacia online vă prezintă primul site farmaceutic profesionist din Republica Moldova. n farmacie şi pe site-ul nostru puteţi găsi peste 5.000 de medicamente omologate n Republica Moldova şi toate produsele parafarmaceutice necesare zi de zi. Astfel, acces nd site-ul nostru, găsiţi toate produsele de care aveţi nevoie fără a mai alerga de la o farmacie la alta şi fără a sta la coadă. Citiţi on line informaţia despre produsele care vă interesează şi comandaţi-le on line cu livrare la domiciliu sau la altă adresa.

    Momentan farmacia nu functioneaza.

    Noutati

    Helmizol

    Intas pharma

    Vagostabyl

    Intas pharma

    Intas pharma

    Subtyl

    Intas pharma

    Intas pharma

    Mekomorivital F

    Intas pharma

    Intas pharma

    Loroben

    Intas pharma

    Intas pharma

    Flurastin

    Intas pharma

    Intas pharma





    Vaccine Safety – Big Pharma Issues, what is big pharma.#What #is #big #pharma

    Vaccine Safety Big Pharma Issues

    Vaccines are the new frontier for the pharmaceutical industry. Here are the reasons drug manufacturers are racing into the vaccine market.

    1. NO LIABILITY: since the passing of the vaccine injury compensation act, drug manufacturers have been shielded from lawsuits by customers injured by their vaccines. This significantly increases the value of vaccines because there is no cost for legal defense or settlements like the 4.85 billion settlement against MERCK for its drug VIOXX.
    2. NO LONG TERM/PLACEBO SAFETY TESTING: Vaccines are not required to go through long term safety studies with real salt water-based placebos. A concise explanation follows:

    In terms of safety studies, a major issue is that most vaccine studies use another vaccine as the control placebo, or use the background substance of the vaccine. There is only one recent study (Cowling 2012) where a true saline placebo was used, rather than another vaccine or the carrier fluid containing everything except the main antigen. That study showed no difference in influenza viral infection between groups but astonishingly it revealed a 5-6 times higher rate of non-influenza viral infections in the vaccinated. It is no small wonder more true placebos are not used in vaccine research. (Source: drsuzanne.net)

    The lack of adequate testing makes vaccines cheaper than drugs to take from trials to market. Furthermore, it is becoming increasingly more expensive to do the long-term safety studies on drugs because the test group cannot be using any other drugs at the time of testing. With over 70% of the US population using prescription drugs this becomes nearly impossible to find. (Source: CBSNews.com)

    MANDATORY VACCINE LAWS:

    Vaccines are one of the only consumer products sold in the U.S. that we are mandated by law to purchase. Laws like California’s SB277, passed in 2015, took away all exemptions leaving the government in control over children’s bodies, not parents. In 2015, the Pharmaceutical industry spent 238 million dollars lobbying for new laws and products. (Source: opensecrets.org)

    VACCINE COURT :

    Vaccine court is the popular term which refers to the Office of Special Masters of the U.S. Court of Federal Claims, which administers a no-fault system for litigating vaccine injury claims. These claims against vaccine manufacturers cannot normally be filed in state or federal civil courts, but instead must be heard in the US Court of Federal Claims, sitting without a jury. The program was established by the 1986 National Childhood Vaccine Injury Act (NCVIA), passed by the United States Congress in response to a threat to the vaccine supply due to a 1980s scare over the DPT vaccine. Following large jury awards to some plaintiffs, most DPT vaccine makers had ceased production, and officials feared the loss of herd immunity. (Source: Wikipedia). With the passage of this act and with it, the absence of any liability to manufacturers for damage caused by their vaccines, the US vaccine schedule expanded dramatically.

    THE VACCINE SCHEDULE:

    American children are the most vaccinated in the world. (Sources: NVIC.org CDC.gov)

    • AGE 12 hours: 1 vaccine
    • AGE 2 months: 8 more vaccines
    • AGE 4 months: 7 more vaccines
    • AGE 6 months: 8 more vaccines
    • AGE 12-18 months: 12 more vaccines
    • AGE 2-6 years: 13 more vaccines
    • AGE: 7-18 years: 20 more vaccines

    GRAND TOTAL: 69 vaccinations

    IMPORTANT TO NOTE: The U.S. Has the highest rate of SIDS (Infant mortality) in the industrialized world. The U.S. also gives more vaccines to its citizens than does any other county in the rest of the industrialized world. (Source: WashingtonPost.com)

    NOTES ON HERD IMMUNITY FROM ANDREW WAKEFIELD

    Herd Immunity is a term that is bandied around in defense of mass and mandatory vaccination. What is it and why is it important?

    Let’s set out a working definition of what Herd Immunity is at a functional level in the population: Herd Immunity is the presence of adequate immunity within a population against a specific infection that operates to protect those at high risk of serious infection and consequently, reduce morbidity and mortality from that infection.

    Now let’s separate out Herd Immunity, comparing what it meant in the pre-vaccine era compared with what it means in the vaccine era, using specific infections as examples Read more of Notes on Herd Immunity from Andrew Wakefield





    Over the Counter Drugs – Medication, South Africa, ims data pharma.#Ims #data #pharma

    ims data pharma

    Ims data pharma

    Ims data pharma

    9 things to know about mental health

    1. A mental illness is when your ability to function properly is affected by negative changes in your mood, thoughts, emotions and behaviour.
    2. Most people with mental illness are not violent, only about 3 – 5% of violent acts can be attributed to people with serious mental illness.
    3. Although most people assume that mental health problems are irreversible, with proper treatment, and support, mental health patients can recover completely.
    4. Prevention is better than cure. Focus on a holistic state of wellbeing, pay attention to warning signs, consciously lower your stress levels and go for medical check-ups to make sure you identify the problem before it even starts. Many people assume that mental health problems are a result of personality problems or character flaws, but this is not the case. A history of abuse in any form, a family history of health problems and a brain injury are usually factors.
    5. Coping with a mental illness can be hard but there are things that can help. Join a support group, speak to a close friend about your feelings, keep a journal and try to have an active social life.
    6. Take comfort in this quote: Instead of saying, “I m damaged, I m broken, say I m healing, I m rediscovering myself, and I’m starting over.
    7. If you have a loved one with a mental illness, the best thing that you can do to show support is to educate yourself about the illness. This will ensure that you can be compassionate about what they are going through and they will be more likely to accept your support when they see your efforts.
    8. Mental illness often begins in childhood, so it is important to pay attention to your children for signs that they might have a mental disorder. If treated early, children often make a faster recovery than adults.
    9. Practice mindfulness. Make yourself more aware of the here and now by practicing acceptance of the present moment without judging it. As obsessive, worrying thoughts come in, acknowledge them. Take note of where your mind drifted and how it made you feel. Then, release them. This will quiet your mind and help you stay grounded in the present moment. You can think a thousand stressful thoughts a day, but you can also choose to let those thoughts come and go. Think, don’t hoard.

    Who We Are

    PHARMA DYNAMICS products save South Africans on average up to 50 % vs the originator product.

    Find out more about the Bugwise app

    Your health matters

    Ims data pharma

    Ims data pharma

    Ims data pharma

    Ims data pharma

    Ims data pharma

    Latest News

    Antibiotic resistance (ABR) has increased worldwide, largely because of the overuse and misuse of antibiotic medications, but if left unchecked, experts fear it could claim up to 10 million lives per annum at a cumulative cost of USD100 trillion by





    10th Annual Pharmaceutical Regulatory Affairs Summit Asia 2017 – IBC Asia, an Informa business, pharma

    pharma regulatory

    Pharma regulatory

    With a 9-year track record of successfully bringing to market the latest developments and insights from decision makers, the Pharma Regulatory Affairs Summit remains the only such conference in Asia. Part of the PharmaCon suite of events, the conference affords you the opportunity of getting hot of the press information and networking across various pharma industry segments.

    “Met regulatory affairs from various companies across Asia and exchanged information regarding issues we have faced in registering the product.”

    Astuti Kurniati, Associate Principal Regulatory Specialist, PT Dexa Medical

    Conference Highlights:

    • Regional Government updates on initiatives, reducing backlogs, new guidelines
    • Drug approval bottlenecks – And how to work with regulators to optimise timelines
    • Pharmacovigilance Regulations – REMS vs RMP, PSUR Submissions, and other updates
    • Product Registration, Submission Approval – Masterclass focusing on the region
    • Supply Chain, Labelling and Distribution – Standards and compliance strategies required

    Thought Leadership Keynote

    Pharma regulatory From Trials to Table – The Move Towards a More Patient-Centric Approach

    Ewing Marion Kauffman Foundation and FasterCures, USA

    TEDGlobal 2012 Speaker on “Let’s Pool Our Medical Data”

    View John’s talk at TEDGlobal 2012 [here]

    Pharma regulatory





    Farmacie Online Chisinau, aristo pharma.#Aristo #pharma

    aristo pharma

    Aristo pharma

    Aristo pharma Aristo pharma

    Aristo pharma

    Aristo pharma

    Pe categorii

    Cauta medicament

    Farmacie Online Chişinău

    Farmacia online vă prezintă primul site farmaceutic profesionist din Republica Moldova. n farmacie şi pe site-ul nostru puteţi găsi peste 5.000 de medicamente omologate n Republica Moldova şi toate produsele parafarmaceutice necesare zi de zi. Astfel, acces nd site-ul nostru, găsiţi toate produsele de care aveţi nevoie fără a mai alerga de la o farmacie la alta şi fără a sta la coadă. Citiţi on line informaţia despre produsele care vă interesează şi comandaţi-le on line cu livrare la domiciliu sau la altă adresa.

    Momentan farmacia nu functioneaza.

    Noutati

    Helmizol

    Aristo pharma

    Vagostabyl

    Aristo pharma

    Aristo pharma

    Subtyl

    Aristo pharma

    Aristo pharma

    Mekomorivital F

    Aristo pharma

    Aristo pharma

    Loroben

    Aristo pharma

    Aristo pharma

    Flurastin

    Aristo pharma

    Aristo pharma





    Product Library, Applied Materials, aristo pharma.#Aristo #pharma

    Product Library

    Technology

    Platform

    Solar Technology

    Advanced Process Solutions

    • Low Temperature

    Applications

    Industries

    All Products

    Aristo pharma

    Nokota™ ECD

    The Nokota system expands the Applied Materials suite of electrochemical deposition systems with a high-productivity wafer-level.

    View product detail

    Aristo pharma

    Endura ® CIRRUS™ HT Co PVD

    As integrated circuits and their components continue to scale downward, the dimensions of metal interconnects and contacts between.

    View product detail

    Aristo pharma

    Activity Manager

    In semiconductor manufacturing, unrealized manufacturing capacity, lag‐time due to workstation events and exception handling can all.

    View product detail

    Aristo pharma

    Advanced Maintenance

    Equipment maintenance in pharma is a critical part of ensuring reliable manufacturing processes. Maintenance organizations need.

    View product detail

    Aristo pharma

    Aera4™ Mask Inspection

    Equipped with a new lithography-grade lens, the Aera4 system demonstrates improved signal-to-noise for both standard high-resolution.

    View product detail

    Aristo pharma

    Aeris™-G Plasma Abatement System

    The Applied Aeris™-G system is a pre-pump plasma abatement solution that uses less energy by treating the actual process gas.

    View product detail

    Aristo pharma

    AKT PiVot PVD System for TFT-LCD Array

    The AKT-PiVot 55KV PVD system has a vertical platform for sputtering deposition of metal and pixel ITO materials on glass substrate.

    View product detail

    Aristo pharma

    AKT ® 55KS PECVD

    Applied’s new AKT 55KS PECVD system brings market-leading precision PECVD technology to 2200mm x 2500mm size substrates. It.

    View product detail

    Aristo pharma

    AKT ® Aristo Twin PVD

    A state-of-the-art capacitive touch panel consists of multiple SiO2, ITO, metal and metal alloy films deposited on either one or both.

    View product detail

    Aristo pharma

    AKT ® Electron Beam Array Test

    The AKT Electron Beam Array Test (EBT) system provides dynamic pixel and TFT characterization and functional tests of flat panel matrix.

    View product detail

    Aristo pharma

    AKT ® NEW ARISTO™ Color Filter Sputter System

    As a fully automated vertical in-line sputtering system, the NEW ARISTO provides the highest throughput in the industry. Automated.

    View product detail

    Aristo pharma

    AKT ® -PECVD System for TFT-LCD

    AKT-PECVD systems offer processes for both amorphous silicon (a-Si) and metal oxide (MO) backplane technologies. Available films include.

    View product detail

    Aristo pharma

    AKT ® -PiVot™ DT PVD

    The AKT-PiVot 55K DT PVD and 25K DT PVD systems deposit critical film layers that create TFTs and interconnects on 2200mm x 2500mm and.

    View product detail

    Aristo pharma

    AKT ® -PiVot™ PVD

    The AKT-PiVot system’s modular architecture delivers significantly faster cycle time and enables a large variety of configurations.

    View product detail

    Aristo pharma

    AKT ® -PX PECVD

    The Applied AKT-PX family of PECVD systems deposits highly-uniform low temperature polysilicon (LTPS) films on glass substrates from 1.6.

    View product detail

    Aristo pharma

    ALTA ® 4700plus Mask Patterning

    The ALTA 4700plus system provides cost-effective patterning of binary masks and phase shifting masks (PSM), supporting fast turnaround.

    View product detail

    Aristo pharma

    Analytics & Control

    Pharma manufacturing processes are tightly defined and constrained to meet stringent quality, safety and compliance standards. Within.

    View product detail

    Aristo pharma

    Applied Baccini Esatto Technology™

    Esatto Technology is a powerful combination of hardware, software, qualified consumables and processes that enables cell manufacturers.

    View product detail

    Aristo pharma

    Applied Baccini Soft Line

    The Applied Baccini Soft Line is an integrated, fully automated line for crystalline silicon PV cell production. The line features.

    View product detail

    Aristo pharma

    Applied Baccini ® LTCC – Low Temperature

    Co-Fired Ceramic Equipment

    Combining precision alignment and high throughput substrate handling, Applied’s puncher, screen printer and stacker systems enable.

    View product detail

    Aristo pharma

    Applied PECVD 5.7

    The Applied PECVD 5.7 system deposits the active layers of thin film silicon solar panels on glass substrates up to 5.7m2 in area.

    View product detail

    Aristo pharma

    Applied SmartWeb ®

    The touch panel industry is a dynamic, rapidly-growing business and a key driver of growth for the flat panel display equipment market.

    View product detail

    Aristo pharma

    Applied Tempo™ Metallization System

    The Tempo screen printer sets a new standard in cell manufacturing, supporting fast ramp time to production, a proven industry-record.

    View product detail

    Aristo pharma

    Applied TopBeam™

    TopBeam is available in two basic chamber sizes: TopBeam 1100 / 1100 S series (for roll widths 550 to 1,100 mm) and TopBeam 2850 / 2450.





    Heyl Chemisch-pharmazeutische Fabrik GmbH – Co, pharma chem.#Pharma #chem

    Vitaminbedarf gedeckt?

    Studien aus der ganzen Welt verdeutlichen den unzureichenden Vitamin D-Status in der Bevölkerung.

    Pharma chem

    Morbus Wilson

    Wir tragen Sorge für Menschen mit der seltenen Kupferspeicherkrankheit.

    Pharma chem

    Vergiftungen – Gegenmaßnahmen?

    Wir bieten medizinische Hilfe bei Vergiftungen mit Schwermetallen und Kontaminationen mit Radionukliden.

    Pharma chem

    Pharma chem

    Vergiftungen

    Eine Vergiftung kann jeden Menschen treffen, sei es in beabsichtigter oder unbeabsichtigter Weise. Die Firma Heyl bietet mit ihrer Produktpalette der Antidota medizinisch bedeutsame Gegenmittel bei Vergiftungen mit Schwermetallen und Radionukliden an.

    Pharma chem

    Rheumatoide Arthritis

    Die rheumatoide Arthritis ist die häufigste entzündliche Gelenkerkrankung, an der weltweit 0,5 bis 1 % der Bevölkerung leidet. Die Firma Heyl bietet bereits seit ihrer Gründung Rheumatherapeutika an, die den Betroffenen das Leben mit ihrer Krankheit erleichtern.

    Pharma chem

    Spezieller Vitaminmangel

    Vitamine sind unverzichtbar für viele lebenswichtige Funktionen des menschlichen Körpers. Diese organischen Verbindungen kann unser Organismus nicht oder oft nur in unzureichender Menge selbst synthetisieren. Daher müssen Vitamine mit der Nahrung aufgenommen werden.

    Pharma chem

    Toxoplasmose

    Diese durch einen mikroskopisch kleinen Parasiten verursachte Infektionskrankheit verläuft zwar meist symptomlos, muss aber mit einem Antibiotikum behandelt werden bei Vorliegen einer Schwangerschaft oder bei immungeschwächten Patienten, um schwerwiegende Folgen zu verhindern.

    Pharma chem

    Morbus Wilson

    Menschen, die an dieser erblich bedingten Stoffwechselstörung leiden, können aufgenommenes Kupfer nicht mehr ausscheiden, so dass im unbehandelten Fall schwere Schäden an Gehirn und Leber die Folge sind. Ein gegen Kupfer entwickeltes Antidotum kann hier Mittel der Wahl sein.

    Pharma chem

    Reagenzien

    Spezielle Reagenzien für die Analytik sind in der Gruppe Gnoste [Gnosis (γνῶσις) altgriechisch für Erkenntnis] zusammengefasst.

    Letzte Abstracts

    Wilson JP et al., 2015; Decorporation of systemically distributed americium by a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation in beagle dogs; Health Phys. 108(3) 308-318

    Study design: Beagle dogs received various doses of NanoDTPATM capsules to decorporate administered 241Americium (241Am). Efficacy of NanoDTPATM was compared to intravenously . » Mehr

    Shankar GN et al., 2014; Evaluating the Toxicity of Novel Zn-DTPA Tablet Formulation in Dogs and Rats; Drug Development Research 75: 37-46

    Study design: Beagle dogs were treated with increasing doses of trisodium zinc pentetate (Zn-DTPA) in a novel oral solid tablet form for seven days to determine its toxicity . » Mehr

    Schwartz JB et al. 2016; Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial; J. am Geriatr Soc 64:65-72

    Study design: Randomized double-blind investigation to evaluate the 25 OHD levels in elderly nursing home residents after 16 weeks when 800, 2 000 or 4 000 IU/day or 50 000 . » Mehr

    Välimäki VV et al. 2016; How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? A placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women; Clin. Endocrinology 0:1-8

    Study design: Elderly women received 100 000 or 200 000 IU of vitamin D3 or placebo orally every 3 months plus 1 g of calcium daily over one year to test intermittent . » Mehr





    European pharmaceutical regulatory affairs experts – Pharma-EU, s, pharma regulatory.#Pharma #regulatory

    Pharma-EU.com: Pharmaceutical Regulatory Solutions for the European Union

    Pharma regulatory

    Consultations with patients regarding the package information leaflets. Guaranteed acceptance across the EU for National, MRP, DCP and CPs.

    Pharma regulatory

    Previously tested PILs can be used to support other PILs to create readability testing exemptions.

    Pharma regulatoryReadability Testing of Package Information Leaflets and Bridging for the Generic Industry – download (285 kB)

    European Regulatory Pharmaceutical Consulting Services

    Pharma regulatory

    We can reformat and submit your pharmaceutical’s dossier to any member state in eCTD or CTD format.

    Pharma regulatory

    Our regulatory managers have proven their experience in coordinating and completing European procedures.

    Pharma regulatory

    We can work on-site as well as off-site to coordinate variations and maintenance of existing licenses.

    Pharma regulatory

    Expert support Module 1 for centralized, decentralized, mutual recognition and national procedures.

    Pharma regulatory

    We translate medical documents to all European languages using our network of certified medical translators.

    Preferred Readability Testing Providers for:

    Pharma regulatory

    Pharma regulatory

    Pharma regulatory

    Pharma regulatory

    Pharma regulatory

    Content: (c) 2008 Pharma-EU, s.r.o.

    Pharma regulatory